

文献検索式

第2章 卵巣癌・卵管癌・腹膜癌

CQ01 I期からIIA期と考えられる患者に対して、どのような進行期決定開腹手術が奨められるか？

[データベース] PubMed

[検索日] 2019年2月11日(月)

("Ovarian Neoplasms" [Mesh] AND ("Omentum/surgery" [Mesh] OR "Appendectomy" [Mesh] OR "Laparotomy" [Mesh]) AND ("Neoplasm Staging" [Mesh] AND ("stage I" [TIAB] OR "stage Ia" [TIAB] OR "stage Ib" [TIAB] OR "stage Ic" [TIAB] OR "stage I" [TIAB] OR "stage Ia" [TIAB] OR "stage Ib" [TIAB] OR "stage Ic" [TIAB] OR early stage* [TIAB] OR "staged I" [TIAB] OR "stages I" [TIAB] OR "stages Ia" [TIAB] OR "stages Ib" [TIAB]))) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (staging laparotom* [TIAB] OR omentectom* [TIAB] OR appendectom* [TIAB]) AND ("stage I" [TIAB] OR "stage Ia" [TIAB] OR "stage Ib" [TIAB] OR "stage Ic" [TIAB] OR "stage I" [TIAB] OR "stage Ia" [TIAB] OR "stage Ib" [TIAB] OR "stage Ic" [TIAB] OR early stage* [TIAB] OR "staged I" [TIAB] OR "stages I" [TIAB] OR "stages Ia" [TIAB] OR "stages Ib" [TIAB]))

[データベース] 医中誌 Web

[検索日] 2019年2月11日(月)

(卵巣腫瘍/TH and (網;外科的療法/TH or 虫垂切除/TH or 開腹術/TH) and (腫瘍進行度/TH and (I期/TA or 1期/TA or Ia期/TA or Ia期/TA or Ib期/TA or Ib期/TA or Ic期/TA or Ic期/TA or 早期/TA or 初期/TA))) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣プレナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (大網切除/TA or 虫垂切除/TA or 開腹術/TA or 開腹手術/TA) and (I期/TA or 1期/TA or Ia期/TA or Ia期/TA or Ib期/TA or Ib期/TA or Ic期/TA or Ic期/TA or 早期/TA or 初期/TA))

[データベース] Cochrane Library

[検索日] 2019年2月11日(月)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND ("staging laparotomy":ti,ab,kw OR omentectom*:ti,ab,kw OR appendectom*:ti,ab,kw) AND ("stage I":ti,ab,kw OR "stage Ia":ti,ab,kw OR "stage Ib":ti,ab,kw OR "stage Ic":ti,ab,kw OR "stage I":ti,ab,kw OR "stage Ia":ti,ab,kw OR "stage Ib":ti,ab,kw OR "stage Ic":ti,ab,kw OR "early stage":ti,ab,kw OR "staged I":ti,ab,kw OR "stages I":ti,ab,kw OR "stages Ia":ti,ab,kw OR "stages Ib":ti,ab,kw)

CQ02 術前にII B期以上と考えられる患者に対して、primary debulking surgery (PDS)は奨められるか？

[データベース] PubMed

[検索日] 2019年2月11日(月)

("Ovarian Neoplasms/surgery" [Mesh] AND ("Cytoreduction Surgical Procedures" [Mesh] OR "Peritoneum/surgery" [Mesh] OR "Splenectomy" [Mesh] OR "Appendectomy" [Mesh]) AND ("Neoplasm Staging" [Mesh] AND advanced [TIAB])) OR ((Ovarian Neoplasm* [TI] OR Ovary Neoplasm* [TI] OR Ovary Cancer* [TI] OR Ovarian Cancer* [TI] OR Ovary Tumo* [TI] OR Ovarian Tumo* [TI]) AND advanced [TI] AND (cytoreduction* [TIAB] OR Cytoreductive [TIAB] OR debulking [TIAB]))

2 文献検索式

OR "optimal surgery" [TIAB] OR "diaphragmatic perinectomy" [TIAB] OR "diaphragmatic peritonectomy" [TIAB] OR splenectom* [TIAB] OR appendectom* [TIAB] OR "extensive upper abdominal surgery" [TIAB]))

[データベース] 医中誌 Web

[検索日] 2019年2月11日(月)

(卵巣腫瘍/TH and (細胞減量手術/TH or 腹膜:外科の療法/TH or 腹膜切除/TH or 脾臓摘出術/TH or 虫垂切除/TH) and (腫瘍進行度/TH and (進行/TA or II期/TA or 2期/TA or IIa期/TA or 2a期/TA or IIb期/TA or 2b期/TA or IIc期/TA or 2c期/TA or III期/TA or 3期/TA or IIIa期/TA or 3a期/TA or IIIa1期/TA or 3a1期/TA or IIIa2期/TA or 3a2期/TA or IIIb期/TA or 3b期/TA or IIIc期/TA or 3c期/TA or IV期/TA or 4期/TA or IVa期/TA or 4a期/TA or IVb期/TA or 4b期/TA))) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (細胞減量/TA or 減量手術/TA or 腹膜切除/TA or 脾臓摘出/TA or 虫垂切除/TA) and (進行/TA or II期/TA or 2期/TA or IIa期/TA or 2a期/TA or IIb期/TA or 2b期/TA or IIc期/TA or 2c期/TA or III期/TA or 3期/TA or IIIa期/TA or 3a期/TA or IIIa1期/TA or 3a1期/TA or IIIa2期/TA or 3a2期/TA or IIIb期/TA or 3b期/TA or IIIc期/TA or 3c期/TA or IV期/TA or 4期/TA or IVa期/TA or 4a期/TA or IVb期/TA or 4b期/TA))

[データベース] Cochrane Library

[検索日] 2019年2月11日(月)

(Ovarian Neoplasm*:ti OR Ovary Neoplasm*:ti OR Ovary Cancer*:ti OR Ovarian Cancer*:ti OR Ovary Tumo*:ti OR Ovarian Tumo*:ti) AND (advanced:ti AND epithelial:ti) AND (cytoreduction*:ti,ab,kw OR Cytoreductive:ti,ab,kw OR debulking:ti,ab,kw OR "optimal surgery":ti,ab,kw OR "diaphragmatic perinectomy":ti,ab,kw OR "diaphragmatic peritonectomy":ti,ab,kw OR splenectom*:ti,ab,kw OR appendectom*:ti,ab,kw OR "extensive upper abdominal surgery":ti,ab,kw)

CQ03 II B期以上と考えられる患者に対する初回手術で、骨盤・傍大動脈リンパ節郭清は奨められるか？

[データベース] PubMed

[検索日] 2018年8月13日(月), 9月25日(火)

("Ovarian Neoplasms" [Mesh] AND "Lymph Node Excision" [Mesh] AND ("Pelvis" [Mesh] OR "Aorta" [Mesh])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB]) AND (lymphadenectom* [TIAB] OR Lymph Node Excision* [TIAB]) AND (pelvic* [TIAB] OR pelvis* [TIAB] OR para-aortic* [TIAB] OR paraaortic* [TIAB]))

[データベース] 医中誌 Web

[検索日] 2018年8月13日(月), 9月26日(水)

(卵巣腫瘍/TH and リンパ節郭清/TH and (骨盤/TH or 大動脈/TH)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (リンパ節郭清/TA or リンパ節切除/TA or リンパ節摘出/TA) and (骨盤/TA or 大動脈/TA) and (DATA=pre))

[データベース] Cochrane Library

[検索日] 2018年8月13日(月), 9月26日(水)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw) AND (lymphadenectomy:ti,ab,kw OR Lymph Node Excision:ti,ab,kw) AND (pelvic:ti,ab,kw OR pelvis:ti,ab,kw OR "para-aortic":ti,ab,kw OR paraaortic:ti,ab,kw)

CQ04 初回手術(PDS)で suboptimal surgery となった進行例に対して、interval debulking surgery (IDS) は奨められるか？

[データベース] PubMed

[検索日] 2019年2月18日(月)

("Ovarian Neoplasms/therapy" [Mesh] AND "Cytoreduction Surgical Procedures" [Mesh]) OR ((Ovarian Neoplasm* [TI] OR Ovary Neoplasm* [TI] OR Ovary Cancer* [TI] OR Ovarian Cancer* [TI] OR Ovary Tumo* [TI] OR Ovarian Tumo* [TI]) AND advanced [TI] AND (cytoreduction* [TIAB] OR Cytoreductive [TIAB] OR debulking [TIAB] OR "optimal surgery" [TIAB] OR "suboptimal surgery" [TIAB]))

[データベース] 医中誌 Web

[検索日] 2019年2月18日(月)

(卵巣腫瘍/TH and 細胞減量手術/TH) or ((卵巣腫瘍/TI or 卵巣がん/TI or 卵巣癌/TI or 卵巣ブレンナー腫瘍/TI or 卵巣悪性腫瘍/TI) and (細胞減量/TA or 減量手術/TA) and 進行/TA)

[データベース] Cochrane Library

[検索日] 2019年2月18日(月)

("Ovarian Neoplasm":ti OR "Ovary Neoplasm":ti OR "Ovary Cancer":ti OR "Ovarian Cancer":ti OR "Ovary Tumor":ti OR "Ovarian Tumor":ti) AND advanced:ti AND (cytoreduction*:ti,ab,kw OR Cytoreductive:ti,ab,kw OR debulking:ti,ab,kw OR "optimal surgery":ti,ab,kw OR "suboptimal surgery":ti,ab,kw)

CQ05 進行例に対して、primary debulking surgery (PDS)の代わりに術前化学療法(NAC) + interval debulking surgery (IDS)を行うことは奨められるか？

[データベース] PubMed

[検索日] 2018年9月20日(木)

("Ovarian Neoplasms" [Mesh] AND "Neoadjuvant Therapy" [Mesh] AND ("Drug Therapy" [Mesh] OR "drug therapy" [SH]) AND "Cytoreduction Surgical Procedures" [Mesh]) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND ((neoadjuvant [TIAB] AND (drug therap* [TIAB] OR chemotherap* [TIAB])) OR NAC [TIAB]) AND (cytoreduction* [TIAB] OR Interval debulking surgery* [TIAB] OR IDS [TIAB]))

[データベース] 医中誌 Web

[検索日] 2018年9月20日(木)

(卵巣腫瘍/TH and ネオアジュバント療法/TH and 細胞減量手術/TH) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (((ネオアジュバント/TA or 術前/TA) and (化学療法/TA or 薬物療法/TA)) or NAC/TA) and (細胞減量/TA or 減量手術/TA or "Interval debulking surgery"/TA or IDS/TA))

[データベース] Cochrane Library

[検索日] 2018年9月20日(木)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND ((neoadjuvant:ti,ab,kw AND (drug therap*:ti,ab,kw OR chemotherap*:ti,ab,kw)) OR NAC:ti,ab,kw) AND (cytoreduction*:ti,ab,kw OR Interval debulking surgery*:ti,ab,kw OR IDS:ti,ab,kw)

CQ06 妊孕性温存を希望する患者に、温存治療は奨められるか？

[データベース] PubMed

[検索日] 2019年2月18日(月)

("Ovarian Neoplasms/therapy" [Mesh] AND ("Fertility" [Mesh] OR "Fertility Preservation" [Mesh])) OR ((Ovarian Neoplasm* [TI] OR Ovary Neoplasm* [TI] OR Ovary Cancer* [TI] OR Ovarian Cancer* [TI] OR Ovary Tumo* [TI] OR Ovarian Tumo* [TI]) AND (fertility sparing* [TIAB] OR fertility preserv* [TIAB] OR fertility outcome* [TIAB] OR preserve fertilit* [TIAB] OR fertility conserv* [TIAB] OR conservative [TIAB] OR conserving [TIAB] OR conservatively [TIAB] OR preserving [TIAB] OR ovarian preserv* [TIAB] OR ovaries preserv* [TIAB] OR ovary preserv* [TIAB]))

[データベース] 医中誌 Web

[検索日] 2019年2月18日(月)

(卵巣腫瘍; 治療/TH and (妊孕性温存/TH or 生殖能力/TH)) or ((卵巣腫瘍/TI or 卵巣がん/TI or 卵巣癌/TI or 卵巣プレナー腫瘍/TI or 卵巣悪性腫瘍/TI) and (手術/TA or 外科/TA or 切除/TA or 摘出/TA or 治療/TA or 療法/TA) and (妊孕性/TA or 温存/TA or 生殖能力/TA or 生殖機能/TA))

[データベース] Cochrane Library

[検索日] 2019年2月18日(月)

("Ovarian Neoplasm":ti OR "Ovary Neoplasm":ti OR "Ovary Cancer":ti OR "Ovarian Cancer":ti OR "Ovary Tumor":ti OR "Ovarian Tumor":ti) AND (fertility sparing*:ti,ab,kw OR fertility preserv*:ti,ab,kw OR fertility outcome*:ti,ab,kw OR preserve fertilit*:ti,ab,kw OR fertility conserv*:ti,ab,kw OR conservative:ti,ab,kw OR conserving:ti,ab,kw OR conservatively:ti,ab,kw OR preserving:ti,ab,kw OR ovarian preserv*:ti,ab,kw OR ovaries preserv*:ti,ab,kw OR ovary preserv*:ti,ab,kw) AND (surgery:ti,ab,kw OR surgical:ti,ab,kw OR operation*:ti,ab,kw OR operate*:ti,ab,kw OR treatment*:ti,ab,kw OR therapy:ti,ab,kw OR management*:ti,ab,kw)

CQ07 卵巣癌に対して、開腹手術の代わりに腹腔鏡下手術は奨められるか？

[データベース] PubMed

[検索日] 2019年2月18日(月)

("Ovarian Neoplasms/surgery" [Mesh] AND "Laparoscopy" [Mesh]) OR ((Ovarian Neoplasm* [TI] OR Ovary Neoplasm* [TI] OR Ovary Cancer* [TI] OR Ovarian Cancer* [TI] OR Ovary Tumo* [TI] OR Ovarian Tumo* [TI]) AND Laparoscop* [TIAB] AND (surgery [TIAB] OR surgical [TIAB] OR cytoreducti* [TIAB]))

[データベース] 医中誌 Web

[検索日] 2019年2月18日(月)

(卵巣腫瘍; 外科の療法/TH and 腹腔鏡法/TH) or ((卵巣腫瘍/TI or 卵巣がん/TI or 卵巣癌/TI or 卵巣プレナー腫瘍/TI or 卵巣悪性腫瘍/TI) and (化学療法/TI or 薬物療法/TI) and 腹腔鏡/TA and (手術/TA or 外科/TA or 減量/TA))

[データベース] Cochrane Library

[検索日] 2019年2月18日(月)

("Ovarian Neoplasm":ti OR "Ovary Neoplasm":ti OR "Ovary Cancer":ti OR "Ovarian Cancer":ti OR "Ovary Tumor":ti OR "Ovarian Tumor":ti) AND Laparoscop*:ti,ab,kw AND (surgery:ti,ab,kw OR surgical:ti,ab,kw OR cytoreducti*:ti,ab,kw)

CQ08 腹腔内播種を有すると考えられる患者に対して、診断目的の腹腔鏡下手術は奨められるか？

〔データベース〕 PubMed

〔検索日〕 2019年2月18日(月), 3月29日(金)

((("Ovarian Neoplasms/diagnosis" [Mesh] OR "Ovarian Neoplasms/pathology" [Mesh]) AND ("Laparoscopy" [Mesh] OR "Laparoscopes" [Mesh])) OR ((Ovarian Neoplasm* [TI] OR Ovary Neoplasm* [TI] OR Ovary Cancer* [TI] OR Ovarian Cancer* [TI] OR Ovary Tumo* [TI] OR Ovarian Tumo* [TI] AND Laparoscop* [TIAB] AND (diagnos* [TIAB] OR predict* [TIAB])) OR ((("Ovarian Neoplasms" [Mesh] OR Ovarian Neoplasm* [TI] OR Ovary Neoplasm* [TI] OR Ovary Cancer* [TI] OR Ovarian Cancer* [TI] OR Ovary Tumo* [TI] OR Ovarian Tumo* [TI]) AND port-site metasta* [TIAB]) OR ((("Ovarian Neoplasms" [Mesh] OR Ovarian Neoplasm* [TI] OR Ovary Neoplasm* [TI] OR Ovary Cancer* [TI] OR Ovarian Cancer* [TI] OR Ovary Tumo* [TI] OR Ovarian Tumo* [TI]) AND ("Rupture" [Mesh] OR rupture* [TIAB])) OR ((("Ovarian Neoplasms" [Mesh] OR Ovarian Neoplasm* [TI] OR Ovary Neoplasm* [TI] OR Ovary Cancer* [TI] OR Ovarian Cancer* [TI] OR Ovary Tumo* [TI] OR Ovarian Tumo* [TI]) AND ("Carbon Dioxide" [Mesh] OR "Carbon Dioxide" [TIAB] OR CO2 [TIAB]))

〔データベース〕 医中誌 Web

〔検索日〕 2019年2月18日(月)

((卵巣腫瘍; 診断/TH or 卵巣腫瘍; 病理学/TH) and (腹腔鏡法/TH or 腹腔鏡/TH)) or ((卵巣腫瘍/TI or 卵巣がん/TI or 卵巣癌/TI or 卵巣ブレンナー腫瘍/TI or 卵巣悪性腫瘍/TI) and (化学療法/TI or 薬物療法/TI) and 腹腔鏡/TA and (診断/TA or 病理/TA))

〔データベース〕 Cochrane Library

〔検索日〕 2019年2月18日(月)

("Ovarian Neoplasm":ti OR "Ovary Neoplasm":ti OR "Ovary Cancer":ti OR "Ovarian Cancer":ti OR "Ovary Tumor":ti OR "Ovarian Tumor":ti) AND Laparoscop*:ti,ab,kw AND (diagnos*:ti,ab,kw OR predict*:ti,ab,kw)

CQ09 術式を決定するために、術中迅速病理診断を行うことは奨められるか？

〔データベース〕 PubMed

〔検索日〕 2018年9月28日(金)

((("Genital Neoplasms, Female/pathology" [Mesh] OR "Genital Neoplasms, Female/anatomy and histology" [Mesh] OR "Genital Neoplasms, Female/diagnosis" [Mesh]) AND ("Frozen Sections" [Mesh] OR ("Intraoperative Period" [Mesh] AND "Cytodiagnosis" [Mesh]))) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (frozen section* [TIAB] OR (intraoperative* [TIAB] AND (consultation* [TIAB] OR diagnos* [TIAB] OR assess* [TIAB] OR ovarian mass* [TIAB] OR cytodiaognos* [TIAB])) OR frozen histopatholog* [TIAB]))

〔データベース〕 医中誌 Web

〔検索日〕 2018年9月28日(金)

((生殖器官腫瘍-女性; 診断/TH or 生殖器官腫瘍-女性; 病理学/TH) and (凍結切片/TH or (術中期/TH and (細胞診/TH or 組織診/TH)))) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (術中/TA and (凍結切片/TA or 診断/TA or 摘出標本/TA or 病理組織/TA)))

〔データベース〕 Cochrane Library

〔検索日〕 2018年9月28日(金)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND (frozen section*:ti,ab,kw OR frozen histopatholog*:ti,ab,kw OR (intraoperative*:ti,ab,kw AND (consultation*:ti,ab,kw OR diagnos*:ti,ab,kw

OR assess*:ti,ab,kw OR ovarian mass*:ti,ab,kw OR cytodianos*:ti,ab,kw)))

CQ10 術後に卵巣癌と判明した患者に対して、どのような追加治療が奨められるか？

〔データベース〕 PubMed

〔検索日〕 2018年10月30日(火)

((("Ovarian Neoplasms/surgery" [Mesh] OR ("Ovarian Neoplasms" [Mesh] AND "Laparotomy" [Mesh])) AND "Neoplasm Staging" [Mesh] AND ("Postoperative Period" [Mesh] OR "Postoperative Complications" [Mesh] OR "Postoperative Care" [Mesh] OR "Chemoradiotherapy, Adjuvant" [Mesh] OR "Chemotherapy, Adjuvant" [Mesh] OR "Radiotherapy, Adjuvant" [Mesh] OR postoperative [TIAB] OR post operative* [TIAB] OR adjuvant [TIAB] OR after [TIAB])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (postoperative [TIAB] OR post operative* [TIAB] OR adjuvant [TIAB] OR (after [TIAB] AND (laparotom* [TIAB] OR surger* [TIAB] surgical* [TIAB] OR Ovariectom* [TIAB] OR hysterectom* [TIAB] OR Trachelectom* [TIAB] OR Salpingectom* [TIAB] OR oophorectom* [TIAB] OR Vulvectom* [TIAB]))) AND stag* [TIAB] NOT medline [SB])

〔データベース〕 医中誌 Web

〔検索日〕 2018年10月30日(火)

((卵巣腫瘍;外科的療法/TH or (卵巣腫瘍/TH and 開腹術/TH) and 腫瘍進行度/TH and (術後期/TH or 術後合併症/TH or 術後管理/TH or アジュバント放射線化学療法/TH or アジュバント化学療法/TH or アジュバント放射線療法/TH) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣プレナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (術後/TA or アジュバント/TA) and (治療/TA or 療法/TA or 手術/TA or 外科/TA) and (進行度/TA or ステージ/TA or 追加/TA))

〔データベース〕 Cochrane Library

〔検索日〕 2018年10月30日(火)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND (postoperative:ti,ab,kw OR post operative*:ti,ab,kw OR adjuvant:ti,ab,kw OR (after:ti,ab,kw AND (laparotom*:ti,ab,kw OR surger*:ti,ab,kw surgical*:ti,ab,kw OR Ovariectom*:ti,ab,kw OR hysterectom*:ti,ab,kw OR Trachelectom*:ti,ab,kw OR Salpingectom*:ti,ab,kw OR oophorectom*:ti,ab,kw OR Vulvectom*:ti,ab,kw))) AND stag*:ti,ab,kw

CQ11 初回薬物療法を行う場合、どのようなレジメンが奨められるか？

〔データベース〕 PubMed

〔検索日〕 2019年2月14日(木)

("Ovarian Neoplasms/drug therapy" [Mesh] AND "Drug Therapy, Combination" [Mesh] AND (primary [TIAB] OR first [TIAB])) OR ((Ovarian Neoplasm* [TI] OR Ovary Neoplasm* [TI] OR Ovary Cancer* [TI] OR Ovarian Cancer* [TI] OR Ovary Tumo* [TI] OR Ovarian Tumo* [TI]) AND (Combination Chemotherap* [TIAB] OR Polytherap* [TIAB] OR Combination Drug Therap* [TIAB] OR Polychemotherap* [TIAB] OR maintenance therap* [TIAB]) AND (primary [TIAB] OR first [TIAB]))

〔データベース〕 医中誌 Web

〔検索日〕 2019年2月14日(木)

(卵巣腫瘍;薬物療法/TH and 多剤併用療法/TH and 初回/TA) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣プレナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (多剤併用化学療法/TA or 多剤併用療法/TA or 多剤化学療法/TA) and 初回/TA)

[データベース] Cochrane Library

[検索日] 2019年2月14日(木)

("Ovarian Neoplasm":ti OR "Ovary Neoplasm":ti OR "Ovary Cancer":ti OR "Ovarian Cancer":ti OR "Ovary Tumor":ti OR "Ovarian Tumor":ti) AND ("Combination Chemotherapy":ti,ab,kw OR Polytherap*:ti,ab,kw OR "Combination Drug Therapy":ti,ab,kw OR Polychemotherap*:ti,ab,kw OR "maintenance therapy":ti,ab,kw) AND (primary:ti,ab,kw OR first:ti,ab,kw)

CQ12 初回手術とその後の化学療法により完全寛解が得られた場合、維持療法は奨められるか？

[データベース] PubMed

[検索日] 2019年1月16日(水)

((("Ovarian Neoplasms/drug therapy" [Majr] OR ("Ovarian Neoplasms/therapy" [Majr] AND "Drug Therapy" [Majr])) AND ("Remission Induction" [Mesh] OR "Maintenance Chemotherapy" [Mesh] OR postremission* [TIAB] OR post remission* [TIAB] OR maintenance* [TIAB] OR postoperative* [TIAB] OR post operative* [TIAB])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (chemotherap* [TIAB] OR drug therap* [TIAB]) AND (postremission* [TIAB] OR post remission* [TIAB] OR maintenance* [TIAB] OR postoperative* [TIAB] OR post operative* [TIAB])) NOT medline [SB])

[データベース] 医中誌 Web

[検索日] 2019年1月16日(水)

((卵巣腫瘍;薬物療法/TH or (卵巣腫瘍;治療/TH and 薬物療法/TH)) and (寛解導入/TH or 完全寛解/TA or 寛解維持療法/TH or 維持/TA)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣プレナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (化学療法/TA or 薬物療法/TA) and (寛解後/TA or 維持/TA or 術後/TA) and (DATA=pre))

[データベース] Cochrane Library

[検索日] 2019年1月16日(水)

("Ovarian Neoplasm":ti OR "Ovary Neoplasm":ti OR "Ovary Cancer":ti OR "Ovarian Cancer":ti OR "Ovary Tumor":ti OR "Ovarian Tumor":ti) AND (chemotherap*:ti,ab,kw OR "drug therapy":ti,ab,kw) AND (postremission*:ti,ab,kw OR "post remission":ti,ab,kw OR maintenance*:ti,ab,kw OR postoperative*:ti,ab,kw OR "post operative":ti,ab,kw)

CQ13 初回手術とその後の化学療法により腫瘍が残存した場合、追加治療は奨められるか？

[データベース] PubMed

[検索日] 2019年1月16日(水)

("Ovarian Neoplasms/therapy" [Majr] AND (postremission* [TIAB] OR post remission* [TIAB] OR postoperative [TIAB] OR post operative [TIAB] OR persitant [TIAB] OR recurren* [TIAB])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (therapy [TIAB] OR treatment [TIAB] OR radiotherapy [TIAB]) AND (postremission* [TIAB] OR post remission* [TIAB] OR postoperative [TIAB] OR post operative [TIAB] OR persitant [TIAB] OR recurren* [TIAB])) NOT medline [SB])

[データベース] 医中誌 Web

[検索日] 2019年1月16日(水)

(卵巣腫瘍; 治療/TH and (寛解後/TA or 術後/TA or 治療後/TA or 再発/TA)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (寛解後/TA or 術後/TA or 治療後/TA or 再発/TA) and (DATA=pre))

[データベース] Cochrane Library

[検索日] 2019年1月16日(水)

("Ovarian Neoplasm":ti OR "Ovary Neoplasm":ti OR "Ovary Cancer":ti OR "Ovarian Cancer":ti OR "Ovary Tumor":ti OR "Ovarian Tumor":ti) AND (therapy:ti,ab,kw OR treatment:ti,ab,kw OR radiotherapy:ti,ab,kw) AND (postremission*:ti,ab,kw OR "post remission":ti,ab,kw OR postoperative:ti,ab,kw OR "post operative":ti,ab,kw OR persisitant:ti,ab,kw OR recurren*:ti,ab,kw)

CQ14 初回化学療法としてパクリタキセルとカルボプラチン併用療法 (conventional TC 療法, dose-dense TC 療法) を施行できない場合に, どのようなレジメンが奨められるか?

[データベース] PubMed

[検索日] 2019年2月14日(木)

((("Ovarian Neoplasms/drug therapy" [Majr] AND "Drug Therapy, Combination" [Mesh] AND (primary [TIAB] OR first [TIAB])) NOT ("Carboplatin" [Mesh] AND "Paclitaxel" [Mesh])) OR ((("Ovarian Neoplasms/drug therapy" [Majr] AND "Drug Therapy, Combination" [Mesh] AND (primary [TIAB] OR first [TIAB])) AND ("Bevacizumab" [Mesh] OR "olaparib" [Supplementary Concept])) OR ((Ovarian Neoplasm* [TI] OR Ovary Neoplasm* [TI] OR Ovary Cancer* [TI] OR Ovarian Cancer* [TI] OR Ovary Tumo* [TI] OR Ovarian Tumo* [TI]) AND (Combination Chemotherap* [TIAB] OR Polytherap* [TIAB] OR Combination Drug Therap* [TIAB] OR Polychemotherap* [TIAB] OR maintenance therap* [TIAB])) NOT ((carboplatin [TIAB] AND paclitaxel [TIAB]) OR "conventional TC" [TIAB] OR "every three week TC" [TIAB] OR "weekly TC" [TIAB] OR "dose dense TC" [TIAB]) AND (primary [TIAB] OR first [TIAB])) OR ((Ovarian Neoplasm* [TI] OR Ovary Neoplasm* [TI] OR Ovary Cancer* [TI] OR Ovarian Cancer* [TI] OR Ovary Tumo* [TI] OR Ovarian Tumo* [TI]) AND (Combination Chemotherap* [TIAB] OR Polytherap* [TIAB] OR Combination Drug Therap* [TIAB] OR Polychemotherap* [TIAB] OR maintenance therap* [TIAB]) AND (Bevacizumab [TIAB] OR olaparib [TIAB]) AND (primary [TIAB] OR first [TIAB]))

[データベース] 医中誌 Web

[検索日] 2019年2月14日(木)

(卵巣腫瘍; 薬物療法/TH and 多剤併用療法/TH and 初回/TA) not (Carboplatin/TH and Paclitaxel/TH) or (卵巣腫瘍; 薬物療法/TH and 多剤併用療法/TH and 初回/TA) and (Bevacizumab/TH or Olaparib/TH) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (多剤/TA or 併用/TA) not (((Carboplatin/TA or カルボプラチン/TA) and (Paclitaxel/TA or パクリタキセル/TA)) or TC 療法/TA) and 初回/TA) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (多剤/TA or 併用/TA) and (Bevacizumab/TA or ベバシツマブ/TA or olaparib/TA or オラパリブ/TA) and 初回/TA)

[データベース] Cochrane Library

[検索日] 2019年2月14日(木)

("Ovarian Neoplasm":ti OR "Ovary Neoplasm":ti OR "Ovary Cancer":ti OR "Ovarian Cancer":ti OR "Ovary Tumor":ti OR "Ovarian Tumor":ti) AND ("Combination Chemotherapy":ti,ab,kw OR Polytherap*:ti,ab,kw OR "Combination Drug Therapy":ti,ab,kw OR Polychemotherap*:ti,ab,kw OR "maintenance therapy":ti,ab,kw) AND (primary:ti,ab,kw OR first:ti,ab,kw) NOT ((carboplatin:ti,ab,kw AND paclitaxel:ti,ab,kw) OR "conventional TC":ti,ab,kw OR "every three week TC":ti,ab,kw OR "weekly TC":ti,ab,kw OR "dose dense TC":ti,ab,kw) OR ((("Ovarian Neoplasm":ti OR "Ovary Neoplasm":ti OR "Ovary Cancer":ti

OR "Ovarian Cancer":ti OR "Ovary Tumor":ti OR "Ovarian Tumor":ti) AND ("Combination Chemotherapy":ti,ab,kw OR Polytherap*:ti,ab,kw OR "Combination Drug Therapy":ti,ab,kw OR Polychemotherap*:ti,ab,kw OR "maintenance therapy":ti,ab,kw) AND (primary:ti,ab,kw OR first:ti,ab,kw) AND (Bevacizumab:ti,ab,kw OR olaparib:ti,ab,kw))

CQ15 I期患者に対して、術後化学療法の省略は奨められるか？

〔データベース〕 PubMed

〔検索日〕 2018年10月3日(水)

("Ovarian Neoplasms" [Mesh] AND "Chemotherapy, Adjuvant" [Mesh] AND (early stage* [TIAB] OR stage 1* [TIAB] OR "stage I" [TIAB] OR stage I* [TIAB])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (Adjuvant Chemotherap* [TIAB] OR Adjuvant Drug Therap* [TIAB]) AND (early stage* [TIAB] OR stage 1* [TIAB] OR "stage I" [TIAB] OR stage I* [TIAB])) OR ("Ovarian Neoplasms" [Mesh] AND "Chemotherapy, Adjuvant" [Mesh] AND ("Adenocarcinoma, Clear Cell" [Mesh] OR "Carcinoma, Endometrioid" [Mesh] OR "Adenocarcinoma, Mucinous" [Mesh])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (Adjuvant Chemotherap* [TIAB] OR Adjuvant Drug Therap* [TIAB]) AND (clear cell carcinoma* [TIAB] OR endometrioid carcinoma* [TIAB] OR mutinous carcinoma* [TIAB] OR mucinous carcinoma* [TIAB]))

〔データベース〕 医中誌 Web

〔検索日〕 2018年10月3日(水)

(卵巣腫瘍/TH and アジュバント化学療法/TH and (I期/TA or 1期/TA or 早期/TA or "stage I"/TA or "stage I"/TA or "early stage"/TA)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣プレナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (アジュバント化学療法/TA or アジュバント薬物療法/TA or 術後化学療法/TA or 術後補助化学療法/TA) and (I期/TA or 1期/TA or 早期/TA or "stage I"/TA or "stage I"/TA or "early stage"/TA)) or (卵巣腫瘍/TH and アジュバント化学療法/TH and (明細胞腺癌/TH or 類内膜癌/TH or 粘液腺癌/TH)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣プレナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (アジュバント化学療法/TA or アジュバント薬物療法/TA or 術後化学療法/TA or 術後補助化学療法/TA) and (腎明細胞癌/TA or 腎明細胞がん/TA or 類内膜癌/TA or 類内膜がん/TA or 粘液性癌/TA or 粘液性がん/TA))

〔データベース〕 Cochrane Library

〔検索日〕 2018年10月3日(水)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND (Adjuvant Chemotherap*:ti,ab,kw OR Adjuvant Drug Therap*:ti,ab,kw) AND ("early stage":ti,ab,kw OR "stage I":ti,ab,kw OR "stage I":ti,ab,kw OR "clear cell carcinoma":ti,ab,kw OR "endometrioid carcinoma":ti,ab,kw OR "mutinous carcinoma":ti,ab,kw OR "mucinous carcinoma":ti,ab,kw)

CQ16 組織型別に化学療法のレジメンを変更することは奨められるか？

〔データベース〕 PubMed

〔検索日〕 2018年10月3日(水)

("Ovarian Neoplasms/drug therapy" [Mesh] AND "Clinical Protocols" [Mesh] AND (histological type* [TIAB] OR histologic subtype* [TIAB] OR histological subtype* [TIAB] OR histologic type* [TIAB])

OR histology [TIAB])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (protocol* [TIAB] OR regimen* [TIAB]) AND (histological type* [TIAB] OR histologic subtype* [TIAB] OR histological subtype* [TIAB] OR histologic type* [TIAB])) OR ("Ovarian Neoplasms/drug therapy" [Mesh] AND "Clinical Protocols" [Mesh] AND ("Adenocarcinoma, Clear Cell" [Mesh] OR "Adenocarcinoma, Mucinous" [Mesh])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (protocol* [TIAB] OR regimen* [TIAB]) AND (clear cell carcinoma* [TIAB] OR endometrioid carcinoma* [TIAB] OR mutinous carcinoma* [TIAB] OR mucinous carcinoma* [TIAB]))

[データベース] 医中誌 Web

[検索日] 2018年10月3日(水)

(卵巣腫瘍;薬物療法/TH and 臨床プロトコール/TH and 組織/TA) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (プロトコール/TA or プロトコル/TA or レジメン/TA) and 組織/TA) or (卵巣腫瘍;薬物療法/TH and 臨床プロトコール/TH and (明細胞腺癌/TH or 粘液腺癌/TH)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (プロトコール/TA or プロトコル/TA or レジメン/TA) and (腎明細胞癌/TA or 腎明細胞がん/TA or 類内膜癌/TA or 類内膜がん/TA or 粘液性癌/TA or 粘液性がん/TA))

[データベース] Cochrane Library

[検索日] 2018年10月3日(水)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND (protocol*:ti,ab,kw OR regimen*:ti,ab,kw) AND (histological type*:ti,ab,kw OR histologic subtype*:ti,ab,kw OR histological subtype*:ti,ab,kw OR histologic type*:ti,ab,kw OR "clear cell carcinoma":ti,ab,kw OR "mucinous carcinoma":ti,ab,kw)

CQ17 進行例に対して初回化学療法を行う場合、腹腔内化学療法は奨められるか？

[データベース] PubMed

[検索日] 2019年2月17日(日)

("Ovarian Neoplasms/drug therapy" [Mesh] AND "Injections, Intraperitoneal" [Mesh]) OR ((Ovarian Neoplasm* [TI] OR Ovary Neoplasm* [TI] OR Ovary Cancer* [TI] OR Ovarian Cancer* [TI] OR Ovary Tumo* [TI] OR Ovarian Tumo* [TI]) AND (Intraperitoneal [TIAB] OR HIPEC [TIAB]) AND (drug therap* [TIAB] OR chemotherap* [TIAB]))

[データベース] 医中誌 Web

[検索日] 2019年2月17日(日)

(卵巣腫瘍;薬物療法/TH and 腹腔内投与/TH) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (化学療法/TA or 薬物療法/TA) and 腹腔内/TA)

[データベース] Cochrane Library

[検索日] 2019年2月17日(日)

("Ovarian Neoplasm":ti OR "Ovary Neoplasm":ti OR "Ovary Cancer":ti OR "Ovarian Cancer":ti OR "Ovary Tumor":ti OR "Ovarian Tumor":ti) AND (Intraperitoneal:ti,ab,kw OR HIPEC:ti,ab,kw) AND ("drug therapy":ti,ab,kw OR chemotherap*:ti,ab,kw)

CQ18 化学療法による過敏性反応(HSR)が生じた場合、同一あるいは同系統の薬剤の投与は可能か？

[データベース] PubMed

[検索日] 2019年2月17日(日)

("Genital Neoplasms, Female/drug therapy" [Mesh] OR "Neoplasms/drug therapy" [Majr]) AND "Drug Hypersensitivity" [Mesh]) OR ((Ovarian Neoplasm* [TI] OR Ovary Neoplasm* [TI] OR Ovary Cancer* [TI] OR Ovarian Cancer* [TI] OR Ovary Tumo* [TI] OR Ovarian Tumo* [TI]) AND (Drug Hypersensitivit* [TIAB] OR Drug Allerg* [TIAB] OR hypersensitivity reaction* [TIAB] OR HSR [TIAB] OR HSRs [TIAB])) AND (drug therap* [TIAB] OR chemotherap* [TIAB])) OR ((Drug Hypersensitivit* [TIAB] OR Drug Allerg* [TIAB] OR hypersensitivity reaction* [TIAB] OR HSR [TIAB] OR HSRs [TIAB]) AND (drug therap* [TIAB] OR chemotherap* [TIAB] OR paclitaxel [TIAB])) NOT medline [SB])

[データベース] 医中誌 Web

[検索日] 2019年2月17日(日)

((生殖器腫瘍-女性;薬物療法/TH or 腫瘍;薬物療法/MTH) and 過敏症-薬物/TH) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (化学療法/TA or 薬物療法/TA) and (有害事象/TA or 薬物アレルギー/TA or 薬物過敏症/TA or 薬剤アレルギー/TA or 薬剤過敏症/TA or 薬剤誘発アレルギー/TA or 薬物過敏性/TA or 薬物過敏反応/TA or 薬物誘発アレルギー/TA))

[データベース] Cochrane Library

[検索日] 2019年2月17日(日)

(Neoplasm*:ti OR Cancer*:ti OR Tumo*:ti) AND ("Drug Hypersensitivity":ti,ab,kw OR "Drug Allergy":ti,ab,kw OR "hypersensitivity reaction":ti,ab,kw OR "hypersensitivity reactions":ti,ab,kw OR HSR:ti,ab,kw OR HSRsti,ab,kw) AND ("drug therapy":ti,ab,kw OR chemotherap*:ti,ab,kw)

CQ19 治療後の経過観察で推奨される間隔は？

CQ20 治療後の問診、内診、腫瘍マーカー測定、画像検査は奨められるか？

[データベース] PubMed

[検索日] 2018年12月12日(水)

("Ovarian Neoplasms/therapy" [Mesh] AND ("Postoperative Period" [Mesh] OR "Postoperative Complications" [Mesh] OR "Long-Term Care" [Mesh] OR "Long Term Adverse Effects" [Mesh] OR "Time Factors" [Mesh]) AND "Neoplasm Recurrence, Local" [Mesh] OR "Recurrence" [Mesh]) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (follow up* [TIAB] OR long term* [TIAB] OR after [TIAB] OR time factor* [TIAB] OR Time Interval* [TIAB] OR postoperative [TIAB] OR post operative* [TIAB] OR adjuvant [TIAB] OR prognos* [TIAB]) AND (therapy [TIAB] OR treatment [TIAB] OR surgery [TIAB] OR surgical [TIAB] OR treated [TIAB] OR management [TIAB]) AND recurren* [TIAB] NOT medline [SB])

[データベース] 医中誌 Web

[検索日] 2018年12月12日(水)

((卵巣腫瘍/TH and (SH= 治療,薬物療法,外科的療法,放射線療法) and (術後期/TH or 術後合併症/TH or 術後管理/TH or 予後/TH) and (時間因子/TH or 長期療養/TH or 治療後長期有害影響/TH) and (再発/TH or 腫瘍再発/TH))) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (治療後/TA or 術後/TA or アジュバント/TA) and (治療/TA or 療法/TA or 手術/TA or 外科/TA) and (長期療養/TA or 経過観察/TA or 間隔/TA or 時間因子/TA or 時間スケール/

TA or 時間係数/TA or 時間的因子/TA or 時間的要因/TA or 追跡/TA or フォローアップ/TA) and 再発/TA)

[データベース] Cochrane Library

[検索日] 2018年12月12日(水)

("Ovarian Neoplasm":ti,ab,kw OR "Ovary Neoplasm":ti,ab,kw OR "Ovary Cancer":ti,ab,kw OR "Ovarian Cancer":ti,ab,kw OR "Ovary Tumor":ti,ab,kw OR "Ovarian Tumor":ti,ab,kw) AND ("follow up":ti,ab,kw OR "long term":ti,ab,kw OR after:ti,ab,kw OR "time factor":ti,ab,kw OR "Time Interval":ti,ab,kw OR postoperative:ti,ab,kw OR "post operative":ti,ab,kw OR adjuvant:ti,ab,kw OR prognos*:ti,ab,kw) AND (therapy:ti,ab,kw OR treatment:ti,ab,kw OR surgery:ti,ab,kw OR surgical:ti,ab,kw OR treated:ti,ab,kw OR management:ti,ab,kw) AND recurren*:ti,ab,kw

CQ21 経過観察中に無症状でCA125が上昇した場合、治療は奨められるか？

[データベース] PubMed

[検索日] 2018年10月24日(水)

(Ovarian Neoplasms [Mesh] AND ("Neoplasm Recurrence, Local" [Mesh] OR "Recurrence" [Mesh]) AND "CA-125 Antigen" [Mesh]) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB] OR Ovarian Carcinoma* [TIAB]) AND (recurrence [TIAB] OR recurrent* [TIAB])) AND (CA 125* [TIAB] OR CA125* [TIAB]))

[データベース] 医中誌 Web

[検索日] 2018年10月24日(水)

(卵巣腫瘍/TH and (腫瘍再発/TH or 再発/TH) and CA-125抗原/TH) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and 再発/TA and (CA-125/TA or "CA 125"/TA OR CA125/TA))

[データベース] Cochrane Library

[検索日] 2018年10月24日(水)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND (recurrence:ti,ab,kw OR recurrent*:ti,ab,kw) AND ("CA 125":ti,ab,kw OR CA125*:ti,ab,kw)

CQ22 卵巣癌治療中や治療終了後にホルモン補充療法(HRT)は奨められるか？

[データベース] PubMed

[検索日] 2018年10月1日(月)

("Ovarian Neoplasms" [Mesh] AND "Hormone Replacement Therapy" [Mesh]) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (hormone replacement therap* [TIAB] OR estrogen replacement* [TIAB] OR HRT [TIAB]))

[データベース] 医中誌 Web

[検索日] 2018年10月1日(月)

(卵巣腫瘍/TH and ホルモン補充療法/TH) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (ホルモン補充療法/TA or ホルモン代償療法/TA or エストロゲン補充療法/TA or エストロゲン代償療法/TA or "hormone replacement"/TA OR "estrogen replacement"/TA))

[データベース] Cochrane Library

[検索日] 2018年10月1日(月)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND (hormone replacement therap*:ti,ab,kw OR estrogen replacement*:ti,ab,kw OR "hormone therapy":ti,ab,kw OR "estrogen therapy":ti,ab,kw OR HRT:ti,ab,kw)

CQ23 乳癌未発症の *BRCA1* あるいは *BRCA2* 変異保持者に対して、リスク低減卵管卵巣摘出術 (RRSO) は奨められるか？

[データベース] PubMed

[検索日] 2018年9月27日(木)

((("Ovarian Neoplasms/surgery" [Mesh] OR ("Ovarian Neoplasms" [Mesh] AND "Gynecologic Surgical Procedures" [Mesh])) AND ("Genes, BRCA1" [Mesh] OR "Genes, BRCA2" [Mesh] OR "BRCA1 Protein" [Mesh] OR "BRCA2 Protein" [Mesh] OR "Mutation" [Mesh])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (BRCA1* [TIAB] OR BRCA2* [TIAB] OR mutation carrier* [TIAB] OR breast cancer 1 gene* [TIAB] OR breast cancer 2 gene* [TIAB] OR BRCA mutation* [TIAB]) AND ((risk-reduc* [TIAB] AND (oophorectom* [TIAB] OR ovariectom* [TIAB] OR surgery [TIAB])) OR RRSO [TIAB]))

[データベース] 医中誌 Web

[検索日] 2018年9月27日(木)

((卵巣腫瘍;外科的療法/TH or (卵巣腫瘍/TH and 婦人科外科/TH)) and (BRCA1 遺伝子/TH or BRCA2 遺伝子/TH or "BRCA1 Protein"/TH or "BRCA2 Protein"/TH or 変異/TH)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (BRCA/TA or 遺伝子変異/TA) and (摘出/TA or oophorectomy/TA or 切除/TA or 外科/TA or 手術/TA) and (risk/TA or リスク/TA or RRSO/TA))

[データベース] Cochrane Library

[検索日] 2018年9月27日(木)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND (BRCA1*:ti,ab,kw OR BRCA2*:ti,ab,kw OR "mutation carrier":ti,ab,kw OR "breast cancer 1 gene":ti,ab,kw OR "breast cancer 2 gene":ti,ab,kw OR "BRCA mutation":ti,ab,kw) AND (("risk-reducing":ti,ab,kw AND (oophorectom*:ti,ab,kw OR ovariectom*:ti,ab,kw OR surgery:ti,ab,kw)) OR RRSO:ti,ab,kw)

第3章 再発卵巣癌・卵管癌・腹膜癌

CQ24 プラチナ製剤抵抗性再発で推奨される薬物療法のレジメンは？

CQ25 プラチナ製剤感受性再発で推奨される薬物療法のレジメンは？

CQ24とCQ25に関しては、2015年版ガイドラインに記載されている文献以降の重要な試験結果・文献は把握しているとの担当作成委員(その後作成委員を辞退)の判断を小委員会でも承認し、日本医学図書館協会による検索式を用いた抽出が行われなかった。

CQ26 再発患者に対して手術療法は奨められるか？

〔データベース〕 PubMed

〔検索日〕 2018年9月22日(土), 11月30日(金), 2019年1月5日(土)

("Ovarian Neoplasms/surgery" [Mesh] AND ("Neoplasm Recurrence, Local" [Mesh] OR "Recurrence" [Mesh])) OR ("Ovarian Neoplasms" [Mesh] AND "Neoplasm Recurrence, Local/surgery" [Mesh]) OR ("Ovarian Neoplasms" [Mesh] AND ("Neoplasm Recurrence, Local" [Mesh] OR "Recurrence" [Mesh]) AND "Gynecologic Surgical Procedures" [Mesh]) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB] OR Ovarian Carcinoma* [TIAB]) AND (recurrence [TIAB] OR recurrent* [TIAB]) AND (surgery [TIAB] OR surgical [TIAB] OR operati* [TIAB] OR operate* [TIAB] OR ovariectom* [TIAB] OR oophorectom* [TIAB]) NOT medline [SB]) OR ("Ovarian Neoplasms/therapy" [Majr] AND ("Neoplasm Recurrence, Local" [Majr] OR "Recurrence" [Majr]) AND "Surgical Procedures, Operative" [Mesh]) OR ("Ovarian Neoplasms/therapy" [Majr] AND ("Neoplasm Metastasis" [Majr] OR "Neoplasms/secondary" [Majr]) AND "Surgical Procedures, Operative" [Mesh]) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB] OR Ovarian Carcinoma* [TIAB]) AND (recurrence [TIAB] OR recurrent* [TIAB] OR metasta* [TIAB]) AND "secondary cytoreductive surgery" [TIAB])

〔データベース〕 医中誌 Web

〔検索日〕 2018年9月22日(土)

(卵巣腫瘍; 外科的療法/TH and 腫瘍再発/TH) or (卵巣腫瘍/TH and 腫瘍再発; 外科的療法/TH) or (卵巣腫瘍/TH and 腫瘍再発/TH and 婦人科外科/TH) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣プレナー腫瘍/TA or 卵巣悪性腫瘍/TA) and 再発/TA and (手術/TA or 外科/TA or 切除/TA or 切開/TA or 摘出/TA) and (DATA=pre))

〔データベース〕 Cochrane Library

〔検索日〕 2018年9月22日(土)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw OR Ovarian Carcinoma*:ti,ab,kw) AND (recurrence:ti,ab,kw OR recurrent*:ti,ab,kw) AND (surgery:ti,ab,kw OR surgical:ti,ab,kw OR operati*:ti,ab,kw OR operate*:ti,ab,kw OR ovariectom*:ti,ab,kw OR oophorectom*:ti,ab,kw)

CQ27 手術適応のない再発患者に対して放射線治療は奨められるか？

〔データベース〕 PubMed

〔検索日〕 2018年9月22日(土), 11月30日(金), 2019年1月5日(土), 1月29日(火)

("Ovarian Neoplasms/radiotherapy" [Mesh] AND ("Neoplasm Recurrence, Local" [Mesh] OR "Recurrence" [Mesh])) OR ("Ovarian Neoplasms" [Mesh] AND "Neoplasm Recurrence, Local/radiotherapy" [Mesh]) OR ("Ovarian Neoplasms" [Mesh] AND ("Neoplasm Recurrence, Local" [Mesh] OR "Recurrence" [Mesh]) AND "Radiotherapy" [Mesh]) OR (Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB] OR Ovarian Carcinoma* [TIAB]) AND (recurrence [TIAB] OR recurrent* [TIAB]) AND (radiotherapy [TIAB] OR radiation therap* [TIAB] OR irradiation [TIAB] OR reirradiation [TIAB])) OR ((Ovarian Neoplasms" [Mesh] AND ("Neoplasm Recurrence, Local" [Mesh] OR "Recurrence" [Mesh]) AND "Radiosurgery" [Mesh]) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB] OR Ovarian Carcinoma* [TIAB]) AND (recurrence [TIAB] OR recurrent* [TIAB] OR metasta* [TIAB]) AND (Stereotactic body radiotherap* [TIAB] OR SBRT [TIAB]))) OR

((("Ovarian Neoplasms/radiotherapy" [Mesh] AND ("Neoplasm Metastasis" [Mesh] OR "Neoplasms/secondary" [Mesh])) OR ("Ovarian Neoplasms" [Mesh] AND ("Neoplasm Metastasis" [Mesh] OR "Neoplasms/secondary" [Mesh]) AND "Radiotherapy" [Mesh]) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB] OR Ovarian Carcinoma* [TIAB]) AND metasta* [TIAB] AND (radiotherapy [TIAB] OR radiation therap* [TIAB] OR irradiation [TIAB] OR reirradiation [TIAB] OR radiosurgery [TIAB]))) OR ("Brain Neoplasms/radiotherapy" [Mesh] AND "Radiotherapy" [Mesh] AND "Brain Neoplasms/secondary" [Mesh]))

[データベース] 医中誌 Web

[検索日] 2018年9月22日(土)

(卵巣腫瘍;放射線療法/TH and 腫瘍再発/TH) or (卵巣腫瘍/TH and 腫瘍再発;放射線療法/TH) or (卵巣腫瘍/TH and 腫瘍再発/TH and 放射線療法/TH) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and 再発/TA and (放射線療法/TA or 放射線治療/TA or 照射治療/TA or 照射療法/TA or 体内照射/TA or 全身照射/TA))

[データベース] Cochrane Library

[検索日] 2018年9月22日(土)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw OR Ovarian Carcinoma*:ti,ab,kw) AND (recurrence:ti,ab,kw OR recurrent*:ti,ab,kw) AND (radiotherapy:ti,ab,kw OR "radiation therapy":ti,ab,kw OR irradiation:ti,ab,kw OR reirradiation:ti,ab,kw)

CQ28 腸閉塞に対して手術療法、薬物療法は奨められるか？

[データベース] PubMed

[検索日] 2019年2月10日(日)

((("Neoplasms/complications" [Majr] OR "Genital Neoplasms, Female/complications" [Mesh]) AND ("Intestinal Obstruction/surgery" [Mesh] OR ("Intestinal Obstruction/therapy" [Majr] AND surgery [TIAB])) AND ("Palliative Care" [Mesh] OR "palliative care" [TIAB] OR palliative surg* [TIAB] OR "Supportive Care" [TIAB] OR "Quality of Life" [Mesh] OR "Quality of Life" [TIAB])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (Intestinal Obstruction* [TIAB] OR bowel obstruction* [TIAB]) AND ("palliative care" [TIAB] OR palliative surg* [TIAB] OR "Supportive Care" [TIAB])) OR ((("Neoplasms/complications" [Majr] OR "Ovarian Neoplasms/complications" [Mesh]) AND ("Intestinal Obstruction/surgery" [Mesh] OR ("Intestinal Obstruction/therapy" [Mesh] AND "Surgical Procedures, Operative" [Mesh])) AND ("Drainage" [Mesh] OR "Gastrostomy" [Mesh])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB] OR "gastroenteric cancer" [TIAB]) AND (Intestinal Obstruction* [TIAB] OR bowel obstruction* [TIAB]) AND (drainage* [TIAB] OR gastrostom* [TIAB])) OR ((("Neoplasms/complications" [Majr] OR "Ovarian Neoplasms/complications" [Mesh] OR "Neoplasms/drug therapy" [Mesh]) AND ("Intestinal Obstruction/drug therapy" [Mesh] OR ("Intestinal Obstruction/therapy" [Mesh] AND ("Drug Therapy" [Mesh] OR "drug therapy" [SH])) AND ("Steroids/therapeutic use" [Mesh] OR "Adrenal Cortex Hormones/therapeutic use" [Mesh] OR "Octreotide/therapeutic use" [Mesh] OR "Scopolamine/therapeutic use" [Mesh] OR "Cholinergic Antagonists/therapeutic use" [Mesh] OR "Histamine H2 Antagonists/therapeutic use" [Mesh] OR "Proton Pump Inhibitors/therapeutic use" [Mesh] OR "Antiemetics/therapeutic use" [Mesh] OR ("Cholinergic Antagonists" [Pharmacological Action] OR "Histamine H2 Antagonists" [Pharmacological Action] OR "Proton Pump Inhibitors" [Pharmacological Action] OR "Antiemetics" [Pharmacological Action]) AND "therapeutic use" [SH])) OR ((Ovarian

Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB] OR "end-stage cancer" [TIAB] OR "anticancer therapy" [TIAB]) AND (Intestinal Obstruction* [TIAB] OR bowel obstruction* [TIAB]) AND (Steroid* [TIAB] OR Corticosteroid* [TIAB] OR Octreotide* [TIAB] OR Scopolamine* [TIAB] OR Anticholinergic* [TIAB] OR "Histamine h2 receptor antagonist" [TIAB] OR Proton pump inhibitor* [TIAB] OR Antiemetic* [TIAB] OR dexamethasone [TIAB]))

[データベース] 医中誌 Web

[検索日] 2019年2月10日(日)

(卵巣腫瘍/TH and (腸閉塞;外科的療法/TH or (腸閉塞/TH and 外科手術/TH)) and (緩和ケア/TH or 生活の質/TH)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (腸閉塞/TA or イレウス/TA or 消化管閉塞/TA or 腸管閉塞/TA) and 緩和/TA) or (卵巣腫瘍/TH and (腸閉塞;外科的療法/TH or (腸閉塞/TH and 外科手術/TH)) and (ドレナージ/TH or 胃造瘻術/TH)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (腸閉塞/TA or イレウス/TA or 消化管閉塞/TA or 腸管閉塞/TA) and (ドレナージ/TA or 胃造瘻術/TA)) or ((卵巣腫瘍/TH and (腸閉塞;薬物療法/TH or (腸閉塞/TH and 薬物療法/AL)) and (Steroids/TH or 副腎皮質ホルモン/TH or Octreotide/TH or "Scopolamine Hydrobromide"/TH or "Cholinergic Antagonists"/TH or "Histamine H2 Antagonists"/TH or "Proton Pump Inhibitors"/TH or 制吐剤/TH)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (腸閉塞/TA or イレウス/TA or 消化管閉塞/TA or 腸管閉塞/TA) and (Steroid/TA or 副腎皮質ホルモン/TA or Corticoid/TA or Corticosteroid/TA or コルチコイド/TA or コルチコステロイド/TA or Octreotide/TA or Scopolamine/TA or スコポラミン/TA or "Cholinergic Antagonist"/TA or Anticholinergic/TA or "Histamine h2 receptor antagonist"/TA or "Histamine H2 Antagonist"/TA or "Proton pump inhibitor"/TA or Antiemetic/TA or 制吐剤/TA))

[データベース] Cochrane Library

[検索日] 2019年2月10日(日)

("Ovarian Neoplasm":ti,ab,kw OR "Ovary Neoplasm":ti,ab,kw OR "Ovary Cancer":ti,ab,kw OR "Ovarian Cancer":ti,ab,kw OR "Ovary Tumor":ti,ab,kw OR "Ovarian Tumor":ti,ab,kw) AND (Intestinal Obstruction*:ti,ab,kw OR bowel obstruction*:ti,ab,kw) AND (palliative:ti,ab,kw OR surgery:ti,ab,kw OR "Supportive Care":ti,ab,kw) OR ("Ovarian Neoplasm":ti,ab,kw OR "Ovary Neoplasm":ti,ab,kw OR "Ovary Cancer":ti,ab,kw OR "Ovarian Cancer":ti,ab,kw OR "Ovary Tumor":ti,ab,kw OR "Ovarian Tumor":ti,ab,kw) AND (Intestinal Obstruction*:ti,ab,kw OR bowel obstruction*:ti,ab,kw) AND (drainage*:ti,ab,kw OR gastrostom*:ti,ab,kw) OR ("Ovarian Neoplasm":ti,ab,kw OR "Ovary Neoplasm":ti,ab,kw OR "Ovary Cancer":ti,ab,kw OR "Ovarian Cancer":ti,ab,kw OR "Ovary Tumor":ti,ab,kw OR "Ovarian Tumor":ti,ab,kw) AND (Intestinal Obstruction*:ti,ab,kw OR bowel obstruction*:ti,ab,kw) AND (Steroid*:ti,ab,kw OR Corticosteroid*:ti,ab,kw OR Octreotide*:ti,ab,kw OR Scopolamine*:ti,ab,kw OR Anticholinergic*:ti,ab,kw OR "Histamine h2 receptor antagonist":ti,ab,kw OR "Proton pump inhibitor":ti,ab,kw OR Antiemetic*:ti,ab,kw OR dexamethasone:ti,ab,kw)

CQ29 腹水貯留に対して薬物療法, 腹水ドレナージは奨められるか?

[データベース] PubMed

[検索日] 2019年2月10日(日)

((("Neoplasms/complications" [Majr] OR "Ovarian Neoplasms" [Mesh] OR "Neoplasms/pathology" [Mesh]) AND ("Ascites" [Mesh] OR "Ascitic Fluid" [Mesh]) AND "Drainage" [Mesh]) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (ascites [TIAB] OR "Ascitic Fluid" [TIAB] OR "Abdominal distention" [TIAB]) AND (Drainage* [TIAB] OR Paracentesis [TIAB])) OR ((("Neoplasms/complications" [Mesh] OR "Ovarian Neoplasms" [Mesh] OR "Neoplasms/therapy" [Mesh])

AND ("Ascites" [Mesh] OR "Ascitic Fluid" [Mesh]) AND ("Diuretics" [Mesh] OR "Diuretics" [Pharmacological Action])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (ascites [TIAB] OR "Ascitic Fluid" [TIAB] OR "Abdominal distention" [TIAB]) AND Diuretic* [TIAB]) OR (("Neoplasms/complications" [Mesh] OR "Ovarian Neoplasms" [Mesh] OR "Neoplasms/therapy" [Mesh]) AND ("Ascites" [Mesh] OR "Ascitic Fluid" [Mesh]) AND "Peritoneovenous Shunt" [Mesh]) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (ascites [TIAB] OR "Ascitic Fluid" [TIAB] OR "Abdominal distention" [TIAB]) AND (Peritoneovenous Shunt* [TIAB] OR Peritoneo Venous Shunt* [TIAB] OR Peritoneovenous Ascites Shunt* [TIAB] OR LeVeen Shunt* [TIAB]))

[データベース] 医中誌 Web

[検索日] 2019年2月10日(日)

(卵巣腫瘍/TH and (腹水症/TH or 腹水/TH or 腹部膨満/TH) and (ドレナージ/TH or 穿刺術/TH)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (腹水/TA or 腹部膨満/TA) and (ドレナージ/TA or 穿刺/TA)) or (卵巣腫瘍/TH and (腹水症/TH or 腹水/TH or 腹部膨満/TH) and 利尿剤/TH) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (腹水/TA or 腹部膨満/TA) and (利尿剤/TA or 利尿薬/TA)) or (卵巣腫瘍/TH and (腹水症/TH or 腹水/TH or 腹部膨満/TH) and 腹腔静脈短絡術/TH) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (腹水/TA or 腹部膨満/TA) and (腹腔静脈短絡術/TA or 腹腔静脈シャント/TA or 腹腔静脈腹水シャント/TA))

[データベース] Cochrane Library

[検索日] 2019年2月10日(日)

("Ovarian Neoplasm":ti,ab,kw OR "Ovary Neoplasm":ti,ab,kw OR "Ovary Cancer":ti,ab,kw OR "Ovarian Cancer":ti,ab,kw OR "Ovary Tumor":ti,ab,kw OR "Ovarian Tumor":ti,ab,kw) AND (ascites:ti,ab,kw OR "Ascitic Fluid":ti,ab,kw OR "Abdominal distention":ti,ab,kw) AND (Drainage*:ti,ab,kw OR Paracentesis:ti,ab,kw OR Diuretic*:ti,ab,kw OR "Peritoneovenous Shunt":ti,ab,kw OR "Peritoneo Venous Shunt":ti,ab,kw OR "Peritoneovenous Ascites Shunt":ti,ab,kw OR "LeVeen Shunt":ti,ab,kw)

CQ30 3rdライン以降の化学療法が検討される患者に対して、化学療法をさらに行うことは奨められるか?

[データベース] PubMed

[検索日] 2018年11月17日(土)

("Ovarian Neoplasms/drug therapy" [Majr] AND ("Antineoplastic Agents/therapeutic use" [Majr] OR "Antineoplastic Agents" [PA]) AND ("Neoplasm Recurrence, Local" [Majr] OR "Recurrence" [Mesh] OR "Drug Resistance, Neoplasm" [Majr])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (recurrence* [TIAB] OR recurrent* [TIAB] OR resistance* [TIAB] OR resistant* [TIAB]) AND (drug therap* [TIAB] OR chemotherap* [TIAB] OR antineoplastic* [TIAB]) NOT medline [SB]) OR (("Ovarian Neoplasms/drug therapy" [Mesh] OR ("Ovarian Neoplasms/therapy" [Mesh] AND ("Drug Therapy" [Majr] OR "Antineoplastic Agents/therapeutic use" [Mesh] OR "Antineoplastic Agents" [PA]))) AND ("Terminal Care" [Mesh] OR ("Palliative Care" [Mesh] OR "Clinical Decision-Making" [Mesh] OR "Advance Care Planning" [Mesh] OR "Decision Making" [Mesh]))) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (recurrence* [TIAB] OR recurrent* [TIAB] OR resistance* [TIAB] OR resistant* [TIAB]) AND (drug therap* [TIAB] OR

chemotherap* [TIAB] OR antineoplastic* [TIAB]) AND (terminal* [TIAB] OR "end of life" [TIAB] OR palliative* [TIAB] OR Clinical decision making* [TIAB] OR advanced care planning* [TIAB])) OR ("Neoplasms/therapy" [Majr] AND ("Survivors" [Mesh] OR "Attitude to Death" [Mesh]) AND "Terminal Care" [Mesh] AND ("Palliative Care" [Mesh] OR "Clinical Decision-Making" [Mesh] OR "Advance Care Planning" [Mesh] OR "Decision Making" [Mesh]))

[データベース] 医中誌 Web

[検索日] 2018年11月17日(土)

((卵巣腫瘍;薬物療法/MTH or (卵巣腫瘍;治療/TH and 抗腫瘍剤/TH)) and ((腫瘍再発/TH or 再発/TH and 抗腫瘍剤耐性/TH)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (再発/TA or 抵抗性/TA or 無効例/TA or 耐性/TA) and (薬物療法/TA or 化学療法/TA or 抗腫瘍剤/TA or 抗ガン剤/TA or 抗がん剤/TA or 抗癌剤/TA or 抗腫瘍薬/TA or 抗ガン薬/TA or 抗癌薬/TA or 抗がん薬/TA) and (DATA=pre)) or ((卵巣腫瘍;薬物療法/TH or (卵巣腫瘍;治療/TH and (薬物療法/TH or 抗腫瘍剤/TH))) and (腫瘍再発/TH or 再発/TH or 抗腫瘍剤耐性/TH) and (ターミナルケア/TH or 緩和ケア/TH or 臨床的判断/TH or 意思決定/TH or アドバンスケア計画/TH)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (再発/TA or 抵抗性/TA or 無効例/TA or 耐性/TA) and (薬物療法/TA or 化学療法/TA or 抗腫瘍剤/TA or 抗ガン剤/TA or 抗がん剤/TA or 抗癌剤/TA or 抗腫瘍薬/TA or 抗ガン薬/TA or 抗癌薬/TA or 抗がん薬/TA) and (終末期/TA or ターミナル/TA or 緩和/TA or 決定/TA or アドバンスケア計画/TA)) or ((腫瘍;治療/MTH and (緩和ケア/TH or 臨床的判断/TH or 意思決定/TH or アドバンスケア計画/TH or 生存者/TH or 癌サバイバー/TH or 死への態度/TH) and ターミナルケア/TH))

[データベース] Cochrane Library

[検索日] 2018年11月17日(土)

("Ovarian Neoplasm":ti OR "Ovary Neoplasm":ti OR "Ovary Cancer":ti OR "Ovarian Cancer":ti OR "Ovary Tumor":ti OR "Ovarian Tumor":ti) AND (recurrence*:ti OR recurrent*:ti OR resistance*:ti OR resistant*:ti) AND ("drug therapy":ti OR chemotherap*:ti OR antineoplastic*:ti) OR (("Ovarian Neoplasm":ti,ab,kw OR "Ovary Neoplasm":ti,ab,kw OR "Ovary Cancer":ti,ab,kw OR "Ovarian Cancer":ti,ab,kw OR "Ovary Tumor":ti,ab,kw OR "Ovarian Tumor":ti,ab,kw) AND (recurrence*:ti,ab,kw OR recurrent*:ti,ab,kw OR resistance*:ti,ab,kw OR resistant*:ti,ab,kw) AND ("drug therapy":ti,ab,kw OR chemotherap*:ti,ab,kw OR antineoplastic*:ti,ab,kw) AND (terminal*:ti,ab,kw OR "end of life":ti,ab,kw OR palliative*:ti,ab,kw OR "clinical decision making":ti,ab,kw OR "advanced care planning":ti,ab,kw)) and (terminal*:ti,ab,kw and (Neoplasm*:ti,ab,kw OR Cancer*:ti,ab,kw) and (therapy:ti,ab,kw or treatment*:ti,ab,kw or chemotherapy:ti,ab,kw) and ("decision making":ti,ab,kw OR "advanced care planning":ti,ab,kw))

第4章 上皮性境界悪性腫瘍

CQ31 片側付属器摘出術後に境界悪性腫瘍と判明した場合、追加手術は奨められるか？

[データベース] PubMed

[検索日] 2018年11月5日(月)

((("Ovarian Neoplasms/surgery" [Mesh] AND borderline [TIAB]) OR ("Ovarian Neoplasms" [Mesh] AND "Surgical Procedures, Operative" [Mesh] AND borderline [TIAB]) OR (((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND borderline [TIAB]) OR (Ovarian Borderline Neoplasm* [TIAB] OR Ovary Borderline Neoplasm* [TIAB] OR Ovary Borderline Cancer* [TIAB] OR Ovarian Borderline Cancer* [TIAB] OR Ovary Borderline Tumo* [TIAB] OR Ovarian Borderline Tumo* [TIAB]))) AND ("Neoplasm Staging" [Mesh] OR "staging surgery" [TIAB] OR staging laparotom* [TIAB] OR surgical staging* [TIAB]))

〔データベース〕 医中誌 Web

〔検索日〕 2018年11月5日(月)

((卵巣腫瘍;外科の療法/TH and 境界/TA) or (卵巣腫瘍/TH and 外科手術/TH and 境界/TA) or (((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and 境界/TA) or (卵巣境界悪性腫瘍/TA or 卵巣粘液性境界悪性腫瘍/TA or 卵巣類内膜境界悪性腫瘍/TA or 卵巣悪性・境界悪性腫瘍/TA or 境界悪性傍卵巣嚢腫/TA or 境界悪性傍卵巣瘍/TA or 卵巣漿液性境界悪性腫瘍/TA or 卵巣漿液性境界悪性腫瘍/TA or 卵巣上皮性境界悪性腫瘍/TA or 境界性卵巣上皮悪性腫瘍/TA or 卵巣境界悪性病変/TA or 卵巣境界悪性型漿液性腫瘍/TA or 卵巣粘漿液性境界悪性腫瘍/TA or 卵巣漿液性境界悪性腫瘍/TA or 卵巣境界悪性ブレンナー腫瘍/TA or 卵巣明細胞境界悪性腫瘍/TA or 卵巣原発境界悪性腫瘍/TA or 卵巣明細胞性境界悪性腫瘍/TA or 卵巣漿液性境界悪性腫瘍/TA or 卵巣両側性境界悪性腫瘍/TA or 卵巣明細胞境界悪性腫瘍/TA or 卵巣原発明細胞境界悪性腫瘍/TA or 境界悪性型卵巣明細胞腫瘍/TA or 卵巣漿液性境界悪性腫瘍/TA or 卵巣漿液性境界悪性表在性腫瘍/TA or 卵巣境界悪性表在性乳頭状腫瘍/TA or 卵巣境界悪性明細胞腫瘍/TA or 卵巣境界悪性類内膜腫瘍/TA or 卵巣内頸部型粘液性境界悪性腫瘍/TA or 卵巣内頸部様粘液性境界悪性腫瘍/TA or 卵巣粘液性境界悪性腫瘍/TA) and (手術/TA or 外科/TA or 摘出/TA))) and (腫瘍進行度/TH or ステージ判定手術/TA or 外科のステージ判定/TA or ステージ判定術/TA or "staging laparotomy"/TA or "staging surgery"/TA or "surgical staging"/TA)

〔データベース〕 Cochrane Library

〔検索日〕 2018年11月5日(月)

((Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND borderline:ti,ab,kw) OR (Ovarian Borderline Neoplasm*:ti,ab,kw OR Ovary Borderline Neoplasm*:ti,ab,kw OR Ovary Borderline Cancer*:ti,ab,kw OR Ovarian Borderline Cancer*:ti,ab,kw OR Ovary Borderline Tumo*:ti,ab,kw OR Ovarian Borderline Tumo*:ti,ab,kw) AND ("staging surgery":ti,ab,kw OR staging laparotomy:ti,ab,kw OR surgical staging*:ti,ab,kw)

CQ32 腫瘍核出術後に境界悪性腫瘍と判明した場合、どのような妊孕性温存治療が奨められるか？

〔データベース〕 PubMed

〔検索日〕 2018年10月24日(水)

((("Ovarian Neoplasms" [Mesh] AND borderline [TIAB]) OR (((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND borderline [TIAB]) OR (Ovarian Borderline Neoplasm* [TIAB] OR Ovary Borderline Neoplasm* [TIAB] OR Ovary Borderline Cancer* [TIAB] OR Ovarian Borderline Cancer* [TIAB] OR Ovary Borderline Tumo* [TIAB] OR Ovarian Borderline Tumo* [TIAB]))) AND ("Fertility" [Mesh] OR "Fertility Preservation" [Mesh] OR (fertility sparing* [TIAB] OR fertility preserv* [TIAB] OR fertility outcome* [TIAB] OR preserve fertilit* [TIAB] OR fertility conserv* [TIAB] OR conservative surg* [TIAB] OR conservative treatment* [TIAB] OR conservative management* [TIAB] OR conservative operation* [TIAB] OR conserving surg* [TIAB] OR conserving treatment* [TIAB] OR conserving management* [TIAB] OR conserving operation* [TIAB] OR treated conservative* [TIAB] OR conservatively treat* [TIAB] OR preserving surg* [TIAB] OR preserving treatment* [TIAB] OR preserving management* [TIAB] OR preserving operation* [TIAB] OR ovarian preserv* [TIAB] OR ovaries preserv* [TIAB] OR ovary preserv* [TIAB])))

〔データベース〕 医中誌 Web

〔検索日〕 2018年10月24日(水)

((卵巣腫瘍/TH and 境界/TA) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and 境界/TA)) and (妊孕性温存/TH or 生殖能力/TH or 妊孕性温存/TA or 生殖能力/TA or 受精能保存/TA or 受胎能保存/TA or 受胎能力保存/TA or 妊よう性温存/TA or 妊よう性保持/TA or 妊孕性保持/TA or 妊孕性保存/TA or 妊孕能温存/TA or 妊孕能保存/TA or 繁殖可能性保存/

TA)

〔データベース〕 Cochrane Library

〔検索日〕 2018年10月24日(水)

((Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND borderline:ti,ab,kw) OR (Ovarian Borderline Neoplasm*:ti,ab,kw OR Ovary Borderline Neoplasm*:ti,ab,kw OR Ovary Borderline Cancer*:ti,ab,kw OR Ovarian Borderline Cancer*:ti,ab,kw OR Ovary Borderline Tumo*:ti,ab,kw OR Ovarian Borderline Tumo*:ti,ab,kw)) AND (fertility sparing*:ti,ab,kw OR fertility preserv*:ti,ab,kw OR fertility outcome*:ti,ab,kw OR preserve fertilit*:ti,ab,kw OR fertility conserv*:ti,ab,kw OR conservative surg*:ti,ab,kw OR conservative treatment*:ti,ab,kw OR conservative management*:ti,ab,kw OR conservative operation*:ti,ab,kw OR conserving surg*:ti,ab,kw OR conserving treatment*:ti,ab,kw OR conserving management*:ti,ab,kw OR conserving operation*:ti,ab,kw OR treated conservative*:ti,ab,kw OR conservatively treat*:ti,ab,kw OR preserving surg*:ti,ab,kw OR preserving treatment*:ti,ab,kw OR preserving management*:ti,ab,kw OR preserving operation*:ti,ab,kw OR ovarian preserv*:ti,ab,kw OR ovaries preserv*:ti,ab,kw OR ovary preserv*:ti,ab,kw)

CQ33 上皮性境界悪性腫瘍患者に、術後化学療法は奨められるか？

〔データベース〕 PubMed

〔検索日〕 2018年10月3日(水)

"Ovarian Neoplasms/therapy" [Majr] AND (borderline [TI] OR BOT [TI] OR low-malignant potential* [TI])

〔データベース〕 医中誌 Web

〔検索日〕 2018年10月3日(水)

(卵巣腫瘍/TH and アジュバント化学療法/TH and (境界/TA or ボーダーライン/TA or borderline/TA)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (アジュバント化学療法/TA or アジュバント薬物療法/TA or 術後化学療法/TA or 術後補助化学療法/TA) and (境界/TA or ボーダーライン/TA or borderline/TA))

〔データベース〕 Cochrane Library

〔検索日〕 2018年10月3日(水)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND (Adjuvant:ti,ab,kw OR postoperative:ti,ab,kw) AND (Chemotherap*:ti,ab,kw OR Drug Therap*:ti,ab,kw) AND (borderline:ti,ab,kw OR BOT:ti,ab,kw OR "low-malignant potential":ti,ab,kw)

CQ34 上皮性境界悪性腫瘍治療後は、長期間の経過観察が奨められるか？

〔データベース〕 PubMed

〔検索日〕 2018年10月4日(木)

("Ovarian Neoplasms/therapy" [Mesh] OR "Ovarian Neoplasms/diagnosis" [Mesh]) AND ("Prognosis" [Mesh] OR "Follow-Up Studies" [Mesh]) AND (borderline [TIAB] OR BOT [TIAB] OR low-malignant potential* [TIAB])) OR (((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (borderline [TIAB] OR BOT [TIAB] OR low-malignant potential* [TIAB])) OR ("ovarian low malignant potential tumor" [TIAB] OR "serous borderdderline tumor" [TIAB] OR "mucinous

borderline tumor" [TIAB]))AND (prognos* [TIAB] OR follow up* [TIAB]))

[データベース] 医中誌 Web

[検索日] 2018年10月4日(木)

(卵巣腫瘍/TH and (予後/TH or 追跡研究/TH) and (境界/TA or ボーダーライン/TA or borderline/TA)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (経過観察/TA or 予後/TA or 追跡研究/TA) and (境界/TA or ボーダーライン/TA or borderline/TA))

[データベース] Cochrane Library

[検索日] 2018年10月4日(木)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND (prognos*:ti,ab,kw OR follow up*:ti,ab,kw) AND (borderline:ti,ab,kw OR BOT:ti,ab,kw OR "low-malignant potential":ti,ab,kw)

CQ35 上皮性境界悪性腫瘍治療後の再発に対して、手術は奨められるか？

[データベース] PubMed

[検索日] 2018年10月4日(木)

("Ovarian Neoplasms/surgery" [Mesh] AND "Neoplasm Recurrence, Local" [Mesh] AND (borderline [TIAB] OR BOT [TIAB] OR low-malignant potential* [TIAB])) OR (((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (borderline [TIAB] OR BOT [TIAB] OR low-malignant potential* [TIAB])) OR ("ovarian low malignant potential tumor" [TIAB] OR "serous borderline tumor" [TIAB] OR "mucinous borderline tumor" [TIAB]))AND recurren* [TIAB] AND (surgery [TIAB] OR surgical [TIAB] OR surgeon [TIAB] OR operati* [TIAB] OR postoperative [TIAB]))

[データベース] 医中誌 Web

[検索日] 2018年10月4日(木)

(卵巣腫瘍;外科的療法/TH and 腫瘍再発/TH and (境界/TA or ボーダーライン/TA or borderline/TA)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and 再発/TA and (境界/TA or ボーダーライン/TA or borderline/TA) and (外科/TA or 手術/TA))

[データベース] Cochrane Library

[検索日] 2018年10月4日(木)

(Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND recurren*:ti,ab,kw AND (borderline:ti,ab,kw OR BOT:ti,ab,kw OR "low-malignant potential":ti,ab,kw) AND (surgery:ti,ab,kw OR surgical:ti,ab,kw OR surgeon:ti,ab,kw OR operati*:ti,ab,kw OR postoperative:ti,ab,kw)

第5章 胚細胞腫瘍

CQ36 悪性卵巣胚細胞腫瘍に対して、腫瘍減量手術は奨められるか？

[データベース] PubMed

[検索日] 2019年5月11日(土)

("Ovarian Neoplasms" [Mesh] AND "Neoplasms, Germ Cell and Embryonal" [Mesh] AND "Cytoreduction Surgical Procedures" [Mesh]) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (Germ Cell* [TIAB] OR Embryonal* [TIAB]) AND (surgery [TIAB] OR surgical [TIAB]

OR operation* [TIAB] OR operate* [TIAB]) AND (debulking* [TIAB] OR Cytoreduct* [TIAB]))

[データベース] 医中誌 Web

[検索日] 2019年5月11日(土)

(卵巣腫瘍/TH and 胚細胞腫瘍と胎児性腫瘍/TH and 細胞減量手術/TH) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣悪性腫瘍/TA) and (減量/TA or 縮小/TA) and (外科/TA or 手術/TA) and (胚細胞/TA or 胎児性/TA or 生殖細胞/TA))

[データベース] Cochrane Library

[検索日] 2019年5月11日(土)

("Ovarian Neoplasm":ti,ab,kw OR "Ovary Neoplasm":ti,ab,kw OR "Ovary Cancer":ti,ab,kw OR "Ovarian Cancer":ti,ab,kw OR "Ovary Tumor":ti,ab,kw OR "Ovarian Tumor":ti,ab,kw) AND ("Germ Cell":ti,ab,kw OR Embryonal*:ti,ab,kw) AND (surgery:ti,ab,kw OR surgical:ti,ab,kw OR operati*:ti,ab,kw OR operate*:ti,ab,kw) AND (debulking*:ti,ab,kw OR Cytoreduct*:ti,ab,kw)

CQ37 悪性卵巣胚細胞腫瘍に対して、妊孕性温存を必要とする患者では妊孕性温存手術は奨められるか？

[データベース] PubMed

[検索日] 2019年5月11日(土)

("Ovarian Neoplasms" [Mesh] AND "Neoplasms, Germ Cell and Embryonal" [Mesh] AND ("Fertility" [Mesh] OR "Fertility Preservation" [Mesh])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (Germ Cell* [TIAB] OR Embryonal* [TIAB]) AND (surgery [TIAB] OR surgical [TIAB] OR operation* [TIAB] OR operat* [TIAB]) AND (fertility sparing* [TIAB] OR fertility preserv* [TIAB] OR fertility outcome* [TIAB] OR preserve fertilit* [TIAB] OR fertility conserv* [TIAB] OR conservative [TIAB] OR conserving [TIAB] OR conservatively [TIAB] OR preserving [TIAB] OR ovarian preserv* [TIAB] OR ovaries preserv* [TIAB] OR ovary preserv* [TIAB]))

[データベース] 医中誌 Web

[検索日] 2019年5月11日(土)

(卵巣腫瘍/TH and 胚細胞腫瘍と胎児性腫瘍/TH and (妊孕性温存/TH or 生殖能力/TH)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣悪性腫瘍/TA) and (外科/TA or 手術/TA) and (妊孕性/TA or 生殖能力/TA) and (温存/TA or 保存/TA))

[データベース] Cochrane Library

[検索日] 2019年5月11日(土)

("Ovarian Neoplasm":ti,ab,kw OR "Ovary Neoplasm":ti,ab,kw OR "Ovary Cancer":ti,ab,kw OR "Ovarian Cancer":ti,ab,kw OR "Ovary Tumor":ti,ab,kw OR "Ovarian Tumor":ti,ab,kw) AND ("Germ Cell":ti,ab,kw OR Embryonal*:ti,ab,kw) AND (surgery:ti,ab,kw OR surgical:ti,ab,kw OR operati*:ti,ab,kw OR operate*:ti,ab,kw) AND ("fertility sparing":ti,ab,kw OR "fertility preservation":ti,ab,kw OR "fertility outcome":ti,ab,kw OR "preserve fertility":ti,ab,kw OR conservativeti,ab,kw OR conserving:ti,ab,kw OR conservatively:ti,ab,kw OR preserving:ti,ab,kw OR "ovarian preservation":ti,ab,kw OR "ovaries preservation":ti,ab,kw OR "ovary preservation":ti,ab,kw)

CQ38 悪性卵巣胚細胞腫瘍に対して、術後化学療法は奨められるか？

[データベース] PubMed

[検索日] 2018年10月10日(水)
 ("Ovarian Neoplasms" [Mesh] AND "Neoplasms, Germ Cell and Embryonal" [Mesh] AND ("Radiotherapy, Adjuvant" [Mesh] OR "Chemotherapy, Adjuvant" [Mesh])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (Germ Cell* [TIAB] OR Embryonal* [TIAB]) AND (Adjuvant [TIAB] OR postoperative [TIAB]))

[データベース] 医中誌 Web

[検索日] 2018年10月10日(水)
 (卵巣腫瘍/TH and 胚細胞腫瘍と胎児性腫瘍/TH and (アジュバント化学療法/TH or アジュバント放射線療法/TH)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (アジュバント化学療法/TA or アジュバント薬物療法/TA or 術後化学療法/TA or 術後補助化学療法/TA or アジュバント放射線療法/TA or 術後放射線/TA or 術後照射/TA) and (胚細胞/TA or 胎児性/TA or 生殖細胞/TA))

[データベース] Cochrane Library

[検索日] 2018年10月10日(水)
 (Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND (Germ Cell*:ti,ab,kw OR Embryonal*:ti,ab,kw) AND (Adjuvant:ti,ab,kw OR postoperative:ti,ab,kw)

CQ39 悪性卵巣胚細胞腫瘍の初回化学療法後の再発例に対して、化学療法、手術療法、もしくは放射線治療は奨められるか？

[データベース] PubMed

[検索日] 2018年10月11日(木)
 (("Ovarian Neoplasms/drug therapy" [Mesh] OR "Ovarian Neoplasms/radiotherapy" [Mesh] OR "Ovarian Neoplasms/therapy" [Mesh] AND "Radiotherapy" [Mesh]) OR ("Ovarian Neoplasms/therapy" [Mesh] AND "Drug Therapy" [Mesh])) AND "Neoplasms, Germ Cell and Embryonal" [Mesh] AND "Neoplasm Recurrence, Local" [Mesh] OR "Recurrence" [Mesh]) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND recurren* [TIAB] AND (Germ Cell* [TIAB] OR Embryonal* [TIAB]) AND (chemotherap* [TIAB] OR drug therap* [TIAB] OR radiotherap* [TIAB] OR Radiation Therap* [TIAB]))

[データベース] 医中誌 Web

[検索日] 2018年10月11日(木)
 ((卵巣腫瘍;薬物療法/TH or 卵巣腫瘍;放射線療法/TH or (卵巣腫瘍:治療/TH and 薬物療法/TH) or (卵巣腫瘍:治療/TH and 放射線療法/TH)) and 胚細胞腫瘍と胎児性腫瘍/TH and (腫瘍再発/TH or 再発/TH) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣ブレンナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (化学療法/TA or 薬物療法/TA or 放射線療法/TA or 放射線治療/TA) and 再発/TA and (胚細胞/TA or 胎児性/TA or 生殖細胞/TA))

[データベース] Cochrane Library

[検索日]: 2018年10月11日(木)
 (Ovarian Neoplasm*:ti,ab,kw OR Ovary Neoplasm*:ti,ab,kw OR Ovary Cancer*:ti,ab,kw OR Ovarian Cancer*:ti,ab,kw OR Ovary Tumo*:ti,ab,kw OR Ovarian Tumo*:ti,ab,kw) AND (Germ Cell*:ti,ab,kw OR Embryonal*:ti,ab,kw) AND recurren*:ti,ab,kw AND (chemotherap*:ti,ab,kw OR "drug therapy":ti,ab,kw OR radiotherap*:ti,ab,kw OR "Radiation Therapy":ti,ab,kw)

CQ40 悪性卵巣胚細胞腫瘍に対する化学療法後の経過観察で留意すべき点は？

〔データベース〕 PubMed

〔検索日〕 2019年1月6日(日)

((("Ovarian Neoplasms/drug therapy" [Mesh] OR ("Ovarian Neoplasms/therapy" [Mesh] AND "Drug Therapy" [Mesh])) AND "Neoplasms, Germ Cell and Embryonal" [Mesh] AND ("Prognosis" [Mesh] OR "Follow-Up Studies" [Mesh] OR "Neoplasm Metastasis" [Mesh] OR "Neoplasm Recurrence, Local" [Mesh] OR "Neoplasms/secondary" [Mesh] OR "Fertility Preservation" [Mesh] OR "Fertility" [Mesh])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (chemotherap* [TIAB] OR drug therap* [TIAB]) AND germ cell* [TIAB] AND (after [TIAB] OR follow up* [TIAB] OR reproductive function* [TIAB] OR menstrual function* [TIAB] OR ovarian function* [TIAB] OR secondary tumor* [TIAB])))

〔データベース〕 医中誌 Web

〔検索日〕 2019年1月6日(日)

((卵巣腫瘍;薬物療法/TH or (卵巣腫瘍;治療/TH and 薬物療法/TH)) and 胚細胞腫瘍と胎児性腫瘍/TH and (予後/TH or 追跡研究/TH or 腫瘍転移/TH or 腫瘍再発/TH or 腫瘍;転移性/TH or 妊孕性温存/TH or 生殖能力/TH) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣プレナー腫瘍/TA or 卵巣悪性腫瘍/TA) and 胚細胞/TA and (経過観察/TA or 予後/TA or 追跡研究/TA or 再発/TA or 転移/TA or 妊孕性/TA or 卵巣機能/TA))

〔データベース〕 Cochrane Library

〔検索日〕 2019年1月6日(日)

("Ovarian Neoplasm":ti,ab,kw OR "Ovary Neoplasm":ti,ab,kw OR "Ovary Cancer":ti,ab,kw OR "Ovarian Cancer":ti,ab,kw OR "Ovary Tumor":ti,ab,kw OR "Ovarian Tumor":ti,ab,kw) AND ((chemotherap*:ti,ab,kw OR "drug therapy":ti,ab,kw) AND ("germ cell":ti,ab,kw OR embryonal:ti,ab,kw)) AND (after:ti,ab,kw OR "follow up":ti,ab,kw OR "reproductive function":ti,ab,kw OR "menstrual function":ti,ab,kw OR "ovarian function":ti,ab,kw OR "secondary tumor":ti,ab,kw OR metast*:ti,ab,kw OR prognos*:ti,ab,kw OR recurren*:ti,ab,kw OR fertility:ti,ab,kw)

第6章 性索間質性腫瘍**CQ41 性索間質性腫瘍に対して、どのような術式が奨められるか？**

〔データベース〕 PubMed

〔検索日〕 2018年12月12日(水)

((("Sex Cord-Gonadal Stromal Tumors/surgery" [Mesh] OR ("Sex Cord-Gonadal Stromal Tumors/therapy" [Mesh] AND ("Gynecologic Surgical Procedures" [Mesh] OR "Ovarian Neoplasms/surgery" [Mesh]))) AND ("Cytoreduction Surgical Procedures" [Mesh] OR "Neoplasm Staging" [Mesh])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (Sex Cord-Gonadal Stromal Tumor* [TIAB] OR Sex Cord Stromal Tumor* [TIAB] OR Granulosa Cell Tumor* [TIAB] OR Luteoma* [TIAB] OR Leydig Cell Tumor* [TIAB] OR Sertoli Cell Tumor* [TIAB] OR Thecoma* [TIAB]) AND (surgery [TIAB] OR surgical [TIAB] OR operation* [TIAB] OR operate* [TIAB]) AND (debulking* [TIAB] OR staging* [TIAB] OR stage* [TIAB])))

〔データベース〕 医中誌 Web

〔検索日〕 2018年12月12日(水)

((性索間質腫瘍;外科的療法/TH or (性索間質腫瘍/TH and (婦人科外科/TH or 卵巣腫瘍;外科的療法/TH))) and (細胞減量手術/TH or 腫瘍進行度/TH) or (卵巣/TA and (性索間質腫瘍/TA or 性索間質性腫瘍/TA)))

瘍/TA or 硬化性間質性腫瘍/TA or 男女性胚細胞腫/TA or Leydig 細胞腫/TA or Sertoli 細胞腫/TA or 黄体腫/TA or 顆粒膜細胞腫/TA or 莢膜細胞腫/TA) and (ステージ/TA or 進行度/TA or 病期/TA or 減量/TA or 縮小/TA) and (外科/TA or 手術/TA))

[データベース] Cochrane Library

[検索日] 2018 年 12 月 12 日(水)

(Sex Cord-Gonadal Stromal Tumor*:ti,ab,kw OR Sex Cord Stromal Tumor*:ti,ab,kw OR Granulosa Cell Tumor*:ti,ab,kw OR Luteoma*:ti,ab,kw OR Leydig Cell Tumor*:ti,ab,kw OR Sertoli Cell Tumor*:ti,ab,kw OR Thecoma*:ti,ab,kw) AND (surgery:ti,ab,kw OR surgical:ti,ab,kw OR operation*:ti,ab,kw OR operate*:ti,ab,kw) AND (debulking*:ti,ab,kw OR staging*:ti,ab,kw OR stage*:ti,ab,kw)

CQ42 性索間質性腫瘍に対して、妊孕性温存を必要とする患者では妊孕性温存手術は奨められるか？

[データベース] PubMed

[検索日] 2018 年 12 月 12 日(水)

((("Sex Cord-Gonadal Stromal Tumors/surgery" [Mesh] OR ("Sex Cord-Gonadal Stromal Tumors/therapy" [Mesh] AND ("Gynecologic Surgical Procedures" [Mesh] OR "Ovarian Neoplasms/surgery" [Mesh]))) AND "Fertility" [Mesh] OR "Fertility Preservation" [Mesh]) OR ((Sex Cord-Gonadal Stromal Tumor* [TIAB] OR Sex Cord Stromal Tumor* [TIAB] OR Granulosa Cell Tumor* [TIAB] OR Luteoma* [TIAB] OR Leydig Cell Tumor* [TIAB] OR Sertoli Cell Tumor* [TIAB] OR Thecoma* [TIAB]) AND (fertility sparing* [TIAB] OR fertility preserv* [TIAB] OR fertility outcome* [TIAB] OR preserve fertilit* [TIAB] OR fertility conserv* [TIAB] OR conservative [TIAB] OR conserving [TIAB] OR conservatively [TIAB] OR preserving [TIAB] OR ovarian preserv* [TIAB] OR ovaries preserv* [TIAB] OR ovary preserv* [TIAB]) AND (surgery [TIAB] OR surgical [TIAB] OR operation* [TIAB] OR operate* [TIAB] OR treatment* [TIAB] OR therapy [TIAB] OR management* [TIAB])))

[データベース] 医中誌 Web

[検索日] 2018 年 12 月 12 日(水)

((性索間質腫瘍;外科の療法/TH or (性索間質腫瘍/TH and (婦人科外科/TH or 卵巣腫瘍;外科の療法/TH)) and (妊孕性温存/TH or 生殖能力/TH)) or ((性索間質腫瘍/TA or 性索間質性腫瘍/TA or 硬化性間質性腫瘍/TA or 男女性胚細胞腫/TA or Leydig 細胞腫/TA or Sertoli 細胞腫/TA or 黄体腫/TA or 顆粒膜細胞腫/TA or 莢膜細胞腫/TA) and (妊孕性/TA or 生殖能力/TA) and (温存/TA or 保存/TA))

[データベース] Cochrane Library

[検索日] 2018 年 12 月 12 日(水)

(Sex Cord-Gonadal Stromal Tumor*:ti,ab,kw OR Sex Cord Stromal Tumor*:ti,ab,kw OR Granulosa Cell Tumor*:ti,ab,kw OR Luteoma*:ti,ab,kw OR Leydig Cell Tumor*:ti,ab,kw OR Sertoli Cell Tumor*:ti,ab,kw OR Thecoma*:ti,ab,kw) AND (fertility sparing*:ti,ab,kw OR fertility preserv*:ti,ab,kw OR fertility outcome*:ti,ab,kw OR preserve fertilit*:ti,ab,kw OR fertility conserv*:ti,ab,kw OR conservative:ti,ab,kw OR conserving:ti,ab,kw OR conservatively:ti,ab,kw OR preserving:ti,ab,kw OR ovarian preserv*:ti,ab,kw OR ovaries preserv*:ti,ab,kw OR ovary preserv*:ti,ab,kw) AND (surgery:ti,ab,kw OR surgical:ti,ab,kw OR operation*:ti,ab,kw OR operate*:ti,ab,kw OR treatment*:ti,ab,kw OR therapy:ti,ab,kw OR management*:ti,ab,kw)

CQ43 性索間質性腫瘍に対して、術後化学療法もしくは術後放射線治療は奨められるか？

[データベース] PubMed

[検索日] 2019 年 7 月 4 日(木)

("Sex Cord-Gonadal Stromal Tumors" [Mesh] AND ("Chemotherapy, Adjuvant" [Mesh] OR "Radiotherapy, Adjuvant" [Mesh])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (Sex Cord-Gonadal Stromal Tumor* [TIAB] OR Sex Cord Stromal Tumor* [TIAB] OR Granulosa Cell Tumor* [TIAB] OR Luteoma* [TIAB] OR Leydig Cell Tumor* [TIAB] OR Sertoli Cell Tumor* [TIAB] OR Thecoma* [TIAB]) AND (Adjuvant* [TIAB] OR postoperative* [TIAB]) AND (Radiotherap* [TIAB] OR drug therap* [TIAB] OR chemotherap* [TIAB] OR Chemoradiotherap* [TIAB]))

[データベース] 医中誌 Web

[検索日] 2019年7月4日(木)

(性索間質腫瘍/TH and (アジュバント化学療法/TH or アジュバント放射線療法/TH)) or (卵巣/TA and (性索間質腫瘍/TA or 性索間質性腫瘍/TA or 硬化性間質性腫瘍/TA or 男性性胚細胞腫/TA or Leydig 細胞腫/TA or Sertoli 細胞腫/TA or 黄体腫/TA or 顆粒膜細胞腫/TA or 莢膜細胞腫/TA) and (アジュバント化学療法/TA or アジュバント薬物療法/TA or 術後化学療法/TA or 術後補助化学療法/TA or アジュバント放射線療法/TA or 術後放射線療法/TA or 術後放射線治療/TA or 術後照射/TA))

[データベース] Cochrane Library

[検索日] 2019年7月4日(木)

(Sex Cord-Gonadal Stromal Tumor*:ti,ab,kw OR Sex Cord Stromal Tumor*:ti,ab,kw OR Granulosa Cell Tumor*:ti,ab,kw OR Luteoma*:ti,ab,kw OR Leydig Cell Tumor*:ti,ab,kw OR Sertoli Cell Tumor*:ti,ab,kw OR Thecoma*:ti,ab,kw) AND (Adjuvant*:ti,ab,kw OR postoperative*:ti,ab,kw) AND (Radiotherap*:ti,ab,kw OR "drug therapy":ti,ab,kw OR chemotherap*:ti,ab,kw OR Chemoradiotherap*:ti,ab,kw)

CQ44 性索間質性腫瘍の初回化学療法後の再発例に対して、薬物療法、手術療法、もしくは放射線治療は奨められるか？

[データベース] PubMed

[検索日] 2019年7月4日(木)

("Sex Cord-Gonadal Stromal Tumors" [Mesh] AND ("Neoplasm Recurrence, Local" [Mesh] OR "Recurrence" [Mesh]) AND ("Drug Therapy" [Mesh] OR "Surgical Procedures, Operative" [Mesh] OR "Radiotherapy" [Mesh] OR "drug therapy" [SH] OR "surgery" [SH] OR "radiotherapy" [SH])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (Sex Cord-Gonadal Stromal Tumor* [TIAB] OR Sex Cord Stromal Tumor* [TIAB] OR Granulosa Cell Tumor* [TIAB] OR Luteoma* [TIAB] OR Leydig Cell Tumor* [TIAB] OR Sertoli Cell Tumor* [TIAB] OR Thecoma* [TIAB]) AND recurren* [TIAB] AND (radiotherap* [TIAB] OR radiation therap* [TIAB] OR irradiation* [TIAB] OR drug therap* [TIAB] OR chemotherap* [TIAB] OR Chemoradiotherap* [TIAB]))

[データベース] 医中誌 Web

[検索日] 2019年7月4日(木)

(性索間質腫瘍/TH and (腫瘍再発/TH or 再発/TH) and (外科手術/TH or 薬物療法/TH or 放射線療法/TH)) or (卵巣/TA and (性索間質腫瘍/TA or 性索間質性腫瘍/TA or 硬化性間質性腫瘍/TA or 男性性胚細胞腫/TA or Leydig 細胞腫/TA or Sertoli 細胞腫/TA or 黄体腫/TA or 顆粒膜細胞腫/TA or 莢膜細胞腫/TA) and 再発/TA and (外科/TA or 手術/TA or 薬物療法/TA or 薬物治療/TA or 化学療法/TA or 放射線療法/TA or 放射線治療/TA or 照射/TA))

[データベース] Cochrane Library

[検索日] 2019年7月4日(木)

(Sex Cord-Gonadal Stromal Tumor*:ti,ab,kw OR Sex Cord Stromal Tumor*:ti,ab,kw OR Granulosa Cell Tumor*:ti,ab,kw OR Luteoma*:ti,ab,kw OR Leydig Cell Tumor*:ti,ab,kw OR Sertoli Cell Tumor*:ti,ab,kw OR Thecoma*:ti,ab,kw) AND recurren*:ti,ab,kw AND (radiotherap*:ti,ab,kw OR radiation therap*:ti,ab,kw OR irradiation*:ti,ab,kw OR "drug therapy":ti,ab,kw OR chemotherap*:ti,ab,kw OR Chemoradiotherap*:ti,ab,kw)

CQ45 性索間質性腫瘍治療後の経過観察で留意すべき点は？

〔データベース〕 PubMed

〔検索日〕 2019年1月6日(日)

("Ovarian Neoplasms" [Mesh] AND "Sex Cord-Gonadal Stromal Tumors" [Mesh] AND ("Prognosis" [Mesh] OR "Follow-Up Studies" [Mesh] OR "Neoplasm Metastasis" [Mesh] OR "Neoplasm Recurrence, Local" [Mesh] OR "Neoplasms/secondary" [Mesh] OR "Fertility Preservation" [Mesh] OR "Fertility" [Mesh])) OR ((Ovarian Neoplasm* [TIAB] OR Ovary Neoplasm* [TIAB] OR Ovary Cancer* [TIAB] OR Ovarian Cancer* [TIAB] OR Ovary Tumo* [TIAB] OR Ovarian Tumo* [TIAB]) AND (Stromal [TIAB] OR Granulosa Cell* [TIAB]) AND (after [TIAB] OR follow up* [TIAB] OR secondary tumor* [TIAB] OR metastas* [TIAB] OR recurren* [TIAB] OR prognos* [TIAB]))

〔データベース〕 医中誌 Web

〔検索日〕 2019年1月6日(日)

(卵巣腫瘍/TH and 性索間質性腫瘍/TH and (予後/TH or 追跡研究/TH or 腫瘍転移/TH or 腫瘍再発/TH or 腫瘍;転移性/TH)) or ((卵巣腫瘍/TA or 卵巣がん/TA or 卵巣癌/TA or 卵巣プレナー腫瘍/TA or 卵巣悪性腫瘍/TA) and (性索間質性腫瘍/TA or 性索間質性腫瘍/TA or 顆粒膜細胞腫/TA) and (経過観察/TA or 予後/TA or 追跡研究/TA or 再発/TA or 転移/TA))

〔データベース〕 Cochrane Library

〔検索日〕 2019年1月6日(日)

("Ovarian Neoplasm":ti,ab,kw OR "Ovary Neoplasm":ti,ab,kw OR "Ovary Cancer":ti,ab,kw OR "Ovarian Cancer":ti,ab,kw OR "Ovary Tumor":ti,ab,kw OR "Ovarian Tumor":ti,ab,kw) AND (Stromal:ti,ab,kw OR "Granulosa Cell":ti,ab,kw) AND (after:ti,ab,kw OR "follow up":ti,ab,kw OR "secondary tumor":ti,ab,kw OR metastas*:ti,ab,kw OR prognos*:ti,ab,kw OR recurren*:ti,ab,kw)